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In drug development, there are typically a series of preclinical studies that must be completed with new
compounds or regimens before use in humans. A sequence of in vitro assays followed by in vivo testing in
validated animal models to assess the activity against Mycobacterium tuberculosis, pharmacology and
toxicity is generally used for advancing compounds against tuberculosis in a preclinical stage. A plethora
of different assay systems and conditions are used to study the effect of drug candidates on the growth of
M. tuberculosis, making it difﬁcult to compare data from one laboratory to another. The Bill and Melinda
Gates Foundation recognized the scientiﬁc gap to delineate the spectrum of variables in experimental
protocols, identify which of these are biologically signiﬁcant, and converge towards a rationally derived
standard set of optimized assays for evaluating compounds. The goals of this document are to recom-
mend protocols and hence accelerate the process of TB drug discovery and testing.
Data gathered from preclinical in vitro and in vivo assays during personal visits to laboratories and an
electronic survey of methodologies sent to investigators is reported. Comments, opinions, experiences as
well as ﬁnal recommendations from those currently engaged in such preclinical studies for TB drug
testing are being presented. Certain in vitro assays and mouse efﬁcacy models were re-evaluated in the
laboratory as head-to-head experiments and a summary is provided on the results obtained. It is our
hope that this information will be a valuable resource for investigators in the ﬁeld to move forward in an
efﬁcient way and that key variables of assays are included to ensure accuracy of results which can then
be used for designing human clinical trials. This document then concludes with remaining questions and
critical gaps that are in need of further validation and experimentation.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The primary goals of drug development for tuberculosis (TB) are
to shorten and simplify treatment of active TB, provide safer and
more efﬁcacious treatments for drug-resistant TB, eliminate
drugedrug interactions for TB/HIV co-infections, and improve
treatment for latent TB infections. Successful development of new,rts).
-NC-ND license.safe and effective TB therapies faces a number of challenges, some
unique to TB drug discovery and development, many with implica-
tions for other therapeutic indications. For the ﬁrst time in 40 years
there is a portfolio of novel anti-tuberculosis compounds which are
in need of extensive testing as single agents and in combination
regimens before moving on to human clinical trials.1,2 Around ten
drug candidates are now in clinical development and we currently
have the largest pipeline of early-stage projects and compounds in
history.1e3 Although there is deﬁnitely a reason for some optimism,
the current pipeline is likely not sufﬁcient considering the high
attrition rates of compounds in clinical studies.4 Therefore, there is
a deﬁnite need to increase the numbers of compounds at all levels of
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odologies to identify new active compounds. This need is especially
urgent in light of the recent efforts by the Critical Path to New TB
Regimens (CPTR) program, which strives to develop a novel
combination drug regimen for tuberculosis based on 3e4 new drugs
with a novel mechanism of action.5
Typically there are a series of preclinical studies with new
chemical entities that must be completed before use in humans. A
sequence of in vitro assays followed by in vivo testing in validated
animal models to assess the activity against Mycobacterium tuber-
culosis, pharmacology and toxicity is generally used for advancing
compounds in a preclinical stage.6 A plethora of different assay
systems and conditions are used to study the effect of drug candi-
dates on the growth ofM. tuberculosis, making it difﬁcult to compare
data from one laboratory to another. The Bill and Melinda Gates
Foundation recognized the scientiﬁc gap to delineate the spectrum
of variables in experimental protocols, identify which of these are
biologically signiﬁcant, and converge towards a rationally derived
standard set of optimized assays for evaluating compounds. The
question that we are asking here is whether there are more efﬁcient
ways of testing new candidate agents and re-evaluating the current
methodologies of compound testing. The goals of this document are
to recommend protocols and hence accelerate the process of TB drug
discovery and testing. This document is not meant to be a substitute
for the regulatory requirements for drug approvals, but rather to
provide insight into key variables of preclinical assays for the beneﬁt
of all investigators in the ﬁeld. In 2001, a scientiﬁc blueprint was
published to guide the process of preclinical studies, and this
document detailed ways in which to close the gaps that exist in TB
drug discovery and development.5,7 The blueprint celebrates this
year as its 10th anniversary. This document can be seen as an
extension of this blueprint, however, the focus will mainly be on the
in vitro and in vivo methodologies required for activity testing
againstM. tuberculosis and less onmethodologies that are utilized in
drug development in general (such as ADME, pharmacokinetics,
toxicology). In addition, it includes a focused review of the current
and historic methodologies. In the chapters that follow, an assess-
ment of the current state of activities ongoing in laboratories
engaged in TB drug testing methodologies as well as the lessons
learned from experiences in both academic and industrial labora-
tories is presented. Data gathered from preclinical in vitro and in vivo
assays during personal visits to laboratories and an electronic survey
of methodologies sent to investigators is reported. Comments,
opinions, experiences as well as ﬁnal recommendations from those
currently engaged in such preclinical studies for TB drug testing are
being presented. Certain in vitro assays and mouse models were re-
evaluated in our laboratories as head-to-head experiments and
a summary is provided on the results obtained. It is our hope that
this information will be a valuable resource for investigators in the
ﬁeld to move forward in an efﬁcient way and that key variables of
assays are included to ensure accuracy of results which can then be
used for designing human clinical trials. This document then
concludeswith some remaining questions that are in need of further
validation and experimentation.
2. In vitro evaluations of TB drugs
2.1. Historic review
Although the tubercle bacillus was ﬁrst described by Koch in
1882, it would be six more years before media were devised which
allowed for sufﬁcient growth to enable studies of bacillary
composition and antigenicity. The key was the introduction of
glycerol as a carbon source, ﬁrst in the presence of protein/
peptone8,9 and also in its absence,10 the latter being preferred forimmunologic studies. The minimal requirements for growth were
deﬁned as early as 1894 by Proskauer and Beck11 and consisted of
ammonium carbonate, mono-potassium phosphate, magnesium
sulfate and glycerol although they also recognized that simple
amino acids could substitute for ammonium salts.
In the ﬁrst two decades of the 20th century several groups
focused on further studies of the nutrition of the tubercle bacillus
with much attention devoted to amino acids.12 This followed the
discovery that it was actually small amounts of (contaminating)
free amino acids in the protein/peptone preparations available at
that time that supported growth in the early culture media. A
number of single amino acids could serve equally well as the sole
source of nitrogen, most notably arginine, histidine, alanine,
leucine and asparagine but not including those containing
a benzene ring (phenyalanine, tryptophan and tyrosine).13 During
this time the H37 strain (originally isolated in 1905) was widely
employed and the extent of growth was usually described as scant,
moderate or luxuriant.
By the time the ﬁrst useful anti-TB agents were discovered in the
early 1940s there were already numerous culture media developed
for the cultivation of M. tuberculosis. The effects of various media
constituents on growth and inhibition were however still being
described concurrently with the discovery of streptomycin (SM),
para-aminosalicyclic acid (PAS) and isoniazid (INH).14 Crimm and
Martos15 found growth of H37 to be optimal when using an enzy-
matic hydrolysate of casein (“Amigen”) as an alternative to peptone,
individual amino acids or combinations of amino acids. Of the
latter, the combination of phenylalanine, tryptophan and threonine
gave the highest growth yield.
Following the description of the stimulation of oxygen uptake by
salicyclic and benzoic acids,16 the Swedish scientist Jorgen Lehmann
evaluated more than 50 analogs for the ability to inhibit the growth
of Mycobacterium bovis bacillus Calmette-Guérin (BCG) using Sau-
ton’s medium17 and in doing so identiﬁed para-aminosalicylic acid
as the most potent. This was published together with animal
toxicity data and clinical trials results. Compounds at 10mM to 1 mM
were evaluated by the extent of reduction in either pellicle area or
dry weight at a time (12e20 days) when controls had formed
a conﬂuent pellicle. Pellicle area could be determined by compar-
ison to paper circles of known radii.18
The effects of variables such as inoculum size and growth phase
on static versus cidal anti-TB activity were also being elucidated at
this time. Mycobacterium smegmatis (then referred to as the avir-
ulent strain M. tuberculosis hominis 607) was often used in parallel
with the H37Rv strain. It was during this period that the use of non-
ionic detergents19 was ﬁrst employed for the purpose of dispersed
growth,14 and this allowed for the quantitative estimate of growth
in liquid media by measuring turbidity.20,21 Youmans22 argued that
testing of compounds be preferably conducted in simple, chemi-
cally deﬁned media such as ProskauereBeck (a basal medium
containing glycerol, asparagine and salts) and concluded, based on
the testing of over 3000 compounds by the mid-1940s, that in vitro
testing was of value in eliminating inactive compounds from
further consideration.
Dubos used the closely related Kirchner medium to identify
chaulmoogra oil (used clinically for leprosy at the time) as being
active against Mycobacterium avium via turbidometric measure-
ments and then further modiﬁed the medium by adding citrate,
Tween 80, casein hydrolysate and bovine serum albumin for
dispersed growth of M. tuberculosis. The Dubos lab23 described the
protective effect of serum albumin (particularly fraction V) against
the previously recognized toxicity of free fatty acids, although
Youmans and Youmans later found that there was a very narrow
concentration window within which fatty acids would support
growth in the absence of glycerol or protein.24 Dubos also
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the absence of serum or albumin was due to contamination with
small amounts of fatty acids although this toxicity was not apparent
in media containing glycerol. Youmans and Youmans19 noted that
Tween 80 increased or decreased the potency by >3-fold of
compounds tested in a basal, protein-free, medium (containing
only glycerol, asparagine, magnesium citrate, KH2PO4 and K2SO4,
pH 7.0). These effects were abolished for some of the compounds
when albumin was added to the medium. Regardless of this study
and previous reports on both positive and negative effects of Tween
80 on MICs, this detergent was retained in media used by most
groups25 as turbidometric measurement was the only viable broth
dilution-based quantitative substitute for colony forming unit-
based (CFU) assays at that time and to use the former requires
well dispersed growth. The potential effects, however, were eval-
uated whenever a new candidate lead was being proﬁled by testing
in the presence and absence of Tween 80.26
The one exception to the use of visual or photometric deter-
minations of growth described in the early literature was the use by
the Youmans lab of total nitrogen measurement. This was done
using a micro Kjeldahl method for comparison of growth in media
with and without Tween 80 as they recognized the difﬁculty in
visually comparing dispersed and clumped growth.27
While some groups chose to use a single culture medium28 in
their discovery efforts, by the late 1940s several groups began using
multiple media, sometimes including egg-based media,18,29 in their
in vitro assessments of new TB drugs, a practice that continued
thereafter.18,30,31 Drain et al.25 compared the activity of PAS
analogues in 4 different media: Proskauer and Beck (P&B), P&Bwith
10% human serum, Kirchner synthetic medium and Tween-
albumin liquid medium. Although there were differences in
growth rate (Tween-albumin¼ Kirchner> P&Bþ10%serum> P&B),
there was no signiﬁcant difference in inhibitory activities. Steenken
andWolinsky32 used Tween-albumin, P&B and P&B plus 10% (beef)
serum to evaluate the in vitro activity of terramycin (oxytetracy-
cline) against M. tuberculosis H37, noting a reduction in activity
with the latter medium. They later extended this approach to
a wide array of antimicrobial agents.33 It apparently became
common practice at this time to evaluate compounds in the pres-
ence and absence of 10% animal or human serum18,34 if media were
being used that were otherwise devoid of albumin.
Inocula at this time were commonly described in terms of dry
weight, ranging from 1 mg/ml25 to 6 mg/ml,35 however with the
advent of media supporting dispersed growth, it became feasible to
standardize inocula photometrically.36
There is little mention of the use of organic solvents to evaluate
water-insoluble compounds, however Drain et al.25 noted that
propyleneglycol could beused for this purposewithout effect on the
growth ofM. tuberculosis at concentrations up to 1% and this solvent
was also employed by Klip18 in the investigation of calciferol.
While most screening was conducted in liquid media, the
activity of viomycin was ﬁrst observed at ParkeeDavis in 1951 via
cross-streaks of Streptomyces ﬂoridae on solid medium with both
sensitive and SM-resistant M. tuberculosis H37Rv as well as
M. smegmatis.36 Unfortunately, the medium used was not described
for the cross-streak nor for the subsequent MIC tests (although it
was noted that the latter contained serum) that showed the peptide
to be more active against mycobacteria than other bacteria. More
detailed studies at Pﬁzer, where viomycin had been independently
discovered, determined MICs in DuboseDavis liquid medium with
0.02% Tween 80 and 0.5% albumin using a visual readout after 12
days of growth. Inoculum consisted of a 4e6 day liquid culture,
adjusted photometrically.
The various liquid media and methods described above were
used throughout the 1950s in studies of analogs of anti-TB activesmall synthetic molecules,30e34,37,38 nutrients18,39,40 or natural
substances found in serum,41,42 urine,43 tissue44e48 or from
microorganisms26,32,49e53 including mycobacteria.54,55
There were few major changes with respect to in vitro meth-
odology in the 1960s. The stimulus for developing newer variations
of existing culture media came largely from efforts to improve
primary culture with respect to time and for isolation of drug-
resistant and auxotrophic clinical isolates (e.g. adding catalase
and biotin). These were incorporated into the commercialized
Dubos Broth and Middlebrook 7H9-based formulations.
Readouts were still largely limited to visual observation or
spectrophotometric measurement of turbidity in tube cultures
through the mid-1970s until the description of an automatable
radiometric assay for determination of the growth ofM. tuberculosis
e the precursor of the BACTEC 460 system.56 Several years later the
BACTEC 460 was demonstrated to be usable for clinical drug
susceptibility testing.57,58 Although expensive, radiometric and low
throughput by today’s standards, it was by far the most rapid assay
available, returning susceptibility data in 5e7 days. As such it
represented the state-of-the-art for TB drug discovery until the
dawn of the non-radiometric, metabolism-based assays in the
1990s. These new automated clinical drug susceptibility tests
retained the large volume, individual tube/bottle format but now
monitored growth/inhibition via ﬂuorometric detection of oxygen
consumption (MGIT), colorimetric detection of carbon dioxide (MB/
BacT) or detection of a pressure change due to oxygen consumption
(Versa TREK, formerly ESP Culture System II).59 Most of those
involved with drug discovery began to develop and utilize
microplate-based assays60 that employed redox dyes such as
resazurin/Alamar Blue,61 luminescent reporter proteins62 and
ﬂuorescent reporter proteins.63
2.2. Contemporary survey of current practices
2.2.1. Survey results: overview
A ninety ﬁve question survey of protocols and opinions was
conducted of which about half of the questions were devoted to
in vitro and the other half to in vivomethodologies. Responses were
received from 30 investigators from 25 institutions including
government laboratories (18.5%), academic laboratories (56%) and
from the pharmaceutical industry (11%). Of these, 79% of respon-
dents were willing to share their protocols. The survey can be
viewed in its entirety at the following website: www.mrl.colostate.
edu/acceleration.
Those laboratories known to be involved in tuberculosis drug
discovery at the level of in vitro evaluation were surveyed with
respect to the use of bacterial strains, culture media, testing format,
assays types (e.g. primary screening, minimum inhibitory concen-
tration (MIC), etc.), data interpretation and scale of testing. The
groups surveyed were quite diverse with respect to their TB drug
discovery efforts. Some engage in high throughput screening (HTS)
with hit to lead and lead optimization follow-up while others are
focused on one or a few classes of compounds and therefore have
no need for HTS-compatible assays. The diversity of approaches
was reﬂected in the survey results.
Most (70%) of the respondents performed whole cell screening
while 41% performed isolated molecular target assays. This may
have reﬂected a bias in selection of labs thought to be conducting
cellular assays. A smaller percentage (7.4%) performed multicom-
ponent screening (Figure 1).
2.2.1.1. Choice of bacterial strains. As expected the majority of
laboratories used the H37Rv strain from ATCC (#27294). Some did
however report the use of clinical isolates (Figure 2). Only three
groups reported differences in compound activity between strains
Table 1
Composition of the Middlebrook media series and supplements used*.
Common components Variable components
Na2HPO4 2.5 mg Glycerol 2 mg/ml (0.2%)
KH2PO4 1.0 mg Oleic acid 50 mg/ml
NH4SO4 0.5 mg Palmitic acid 5.6 mg/ml
Na glutamate 0.5 mg Albumin, Bovine 5 mg/ml (0.5%)
Na citrate 0.5 mg Dextrose 2 mg/ml (0.2%)
Ferric NH4 citrate 40 mg Catalase 3 mg/ml
MgSO4 50 mg Casitone 0.1 mg/ml
CuSO4 1.0 mg Tween 80 0.5 mg/ml (0.05%)
ZnSO4 1.0 mg WR1339 0.25 mg/ml
CaCl2 0.5 mg NaCl 0.85 mg/ml
Pyridoxine 1 mg pH 6.6  0.2
Biotin 0.5 mg
*Handbook of Microbiological Media, 2nd Edition, Atlas and Parks (Eds.), CRC
Press.257
Figure 1. Survey responses regarding the type of in vitro assay methodology used in TB
drug testing (presented in percentages). Survey question: Which type of in vitro
assay(s) have been used in your laboratory?
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H37Rv susceptibility to new compounds. Another reported at least 2
compounds towhich H37Ra is more sensitive than H37Rv, one being
rifampin (RIF). One laboratory observed that BCG was more
susceptible to nitroimidazoles versus their standard H37Rv strain;
however they did not speculate on the mechanism. Another group
found that >90% of hits on BCG also had activity forM. tuberculosis.
There was no mention of the percentage of TB-active compounds
that were inactive against non-tuberculous surrogates, (i.e. would
be missed in a surrogate-based screen), however, a very recent
publication indicated these ﬁgures to be 50% and 21% for
M. smegmatis and BCG, respectively.64
2.2.1.2. Choice of media. Most of the laboratories utilize a Mid-
dlebrook 7H9-based medium with speciﬁc supplements (Table 1).
A smaller number utilize glycineealanine-salts (GAS) or Sauton’s
medium, both of which are devoid of protein, and investigators
assume higher sensitivity using poorer media. Both ﬁltration and
autoclaving were mentioned as means of sterilization. While
ﬁltration is routinely used for medium supplements with well
recognized heat lability, this method of sterilization was also used
by Becton Dickinson (Salman Siddiqi, personal communication) for
the preparation of the complete commercial BACTEC 12B medium
(the non-radiometric equivalent of Middlebrook 7H12 medium),
which contains the heat-stable 7H9 broth base and supplements,
some of which are heat-labile. In a previous head-to-head
comparison of autoclaved 7H9 base plus ﬁlter-sterilized supple-
ment versus ﬁlter-sterilized complete medium, we noted superior
growth of M. tuberculosis in the latter (S. Franzblau, unpublishedFigure 2. Survey responses regarding the mycobacterial strain used in anti-TB drug
screening assay (presented in percentages). Survey question: Which M. tuberculosis
strain is being used in your MIC assays?observation). The use of ﬁlter-sterilized complete medium also
obviates the need for making 10 concentrated supplement stocks
where solubilizing bovine serum albumin fraction V can be
problematic.
2.2.1.3. Incubation and readout. In contrast to the overnight incu-
bations used for testing for growth inhibition of the majority of
gram-positive and gram-negative bacteria, mycobacteria require
longer incubations due to their longer generation times. All re-
ported incubation temperatures were at 35e37 C. Of 21 respon-
dents performing phenotypic assays with M. tuberculosis, 12 used
microplates with incubation times ranging from 5 to 14 days but
most often between 7 and 10 days. Those reporting use of a tube
format mostly used a visual observation readout with somewhat
longer incubation times of up to 21 days.
Overall approximately one third of respondents used visual
readouts in liquid culture (Figure 3). Alamar Blue or resazurin
reduction was the most frequently used endpoint for those per-
forming microplate assays, with about half using a ﬂuorometric
readout and half using an absorbance or visual readout. At least 5
groups reported use of intracellular ATP measurement and two
of these groups also used luciferase reporter strains. At least
thirty percent of respondents used colony forming units (CFU)
readouts. It is possible that this is an underestimate since some
groups may only have conveyed what they use for primary or
secondary testing and CFU readouts may be used only as
a conﬁrmatory readout. At least 8 groups reported using more
than one endpoint.Figure 3. Survey responses regarding the readout of the in vitro assay for evaluation of
TB compounds (presented in percentages). Survey question: what readout/endpoint is
being used in your MIC assays?
Figure 4. Survey responses regarding the type of compound libraries used for the
evaluation of TB compounds for activity in in vitro assays (presented in percentages).
Survey question: what type of compounds are being used in your high throughput
screening assays?
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ranged fromminutes for luciferase assays to at least 16 h, and more
typically 24 h for the Alamar Blue assay method. Many felt that the
signal to noise ratio was affected by the time of incubation. The
inoculum, temperature, evaporation and compound precipitation
were cited as factors potentially inﬂuencing results.
2.2.1.4. Deﬁning a “hit”. For those groups that conduct primary
screening prior to determining MICs, maximum concentrations
ranged from 2 to 10 mg/ml or in one case 30 mM. One group
mentioned to screen at multiple concentrations from 0.12 to 2 mg/
ml. A 10-fold reduction or 90% inhibition in viability/metabolism
compared to DMSO (drug-free) controls was commonly used to
deﬁne a hit.
2.2.1.5. Control compounds. MICs obtained with clinical anti-TB
agents are used to quality control assay performance. The most
commonly used positive control drugs were isoniazid (INH) and RIF
but SM, ethambutol (EMB), moxiﬂoxacin (MXF), oﬂoxacin (OFL),
levoﬂoxacin (LVF), amikacin (AK) and linezolid (LZD) were also
cited. DMSO alone, erythromycin (EMY) and vancomycin (VAN)
were reported as negative controls. For hypoxic or anaerobic assays,
most laboratories use metronidazole and isoniazid as positive and
negative controls, respectively. When testing is performed in
microplates, these agents are either included in the same plate with
test samples (40% of respondents) or in separate plates (60% of
respondents).
2.2.1.6. Minimum inhibitory concentration (MIC). Some groups
conduct primary screens at ﬁxed concentrations but many deter-
mine MICs for every sample. The former is often conducted for
large-scale screens followed by MICs for all hits. MICs were deter-
mined by at least one group on 2-fold serial dilutions of compounds
using visual observation of the reduction of a redox dye such as
resazurin or Alamar Blue. MICswere variably deﬁned, in some cases
the visual observation of a total inhibition of growth while many
calculate/extrapolate the lowest concentration yielding 50 or 90
percent inhibition with the aid of various programs including
PRISM, WHONET etc. Other examples include the lowest concen-
tration for which luminescence is lower than a 1:100 dilution of
test culture with no drug. Agar dilution MIC was also reported,
based on the absence of growth on drug-containing 7H11 plates.
Incubation time, pH, inoculum, compound solubility, batch of
compound, use of H37Ra (versus H37Rv), media age, compounds
used after prolonged storage, growth phase of the cells, initial OD
and inoculum size are variables found to affect theMIC for standard
anti-TB drugs or experimental compounds at ﬁxed screening
concentrations.
2.2.1.7. Source of compound libraries for HTS. Most of the
compound libraries screened have been commercially available
synthetic (e.g. Chembridge, Tripos, Nanosyn), or natural product
(e.g. Analyticon) collections or proprietary libraries (e.g. Novartis
archive). Biological extracts, usually from academic organizations,
have also been screened (Figure 4).
2.2.1.8. Other assays. Macrophage assays to assess intracellular
activity againstM. tuberculosis are performedwith awide variety of
cell sources including rat cell lines, bone-marrow derived macro-
phages, J774 and THP-1 cells. About half of respondents determine
MBCs by sub-culture from the MIC test while others conducted it as
a separate test.
2.2.1.9. Non-replicating or slowly replicating bacterial assays. Low
oxygen, starvation and nitric oxide (NO)-release assays are used tomeasure the activity of new compounds against non-replicating
(NR) or slowly replicating (SR) TB bacilli. M. tuberculosis, M. smeg-
matis andM. bovis BCG are usually used for these studies. One group
uses the H37Rv strain ofM. tuberculosis for NR and SR assays as well
as BCG and all were chosen because they are standard laboratory
strains and the genome sequences are available. The positive and
negative controls for the NR and SR assays included such agents as
metronidazole, isoniazid (INH), MXF and RIF.
Comments regarding throughput indicated these assays to be
relatively low throughput. Laboratories reported conducting
experiments once every three weeks with only 12e20 compounds
per run, another did 5e10 compounds/week once per week and
another reported doing 2e3 experiments per week.
Themajor variables that affect the outcome of the NR or SR assay
include the head space ratio, abrupt stirring, the rotation per
minute (rpm) of stirring cultures and sealing of vials. Variation in
results is seen with INH (showing slight activity), or with experi-
mental compounds; the latter is usually due to solubility issues.
Other assay variables included the starting inoculum, degree of
anaerobiosis and clumping (for nutrient starvation model). Weak-
nesses of the NR or SR assay system include the fact that the in vivo
relevance of these assays is not known and variable outcomes
between assays. Also mentioned is the lack of suitability for HTS
and lower reproducibility than the regular MIC assay. Assay opti-
mization was mentioned to be critical for the Wayne model to
obtain meaningful results. The strength is its strong ability to
differentiate between sterilizing compounds (such as RIF) and non-
sterilizing compounds (such as INH) against NR/SR M. tuberculosis.
A perceived strength is that it is a good indicator of efﬁcacy against
non-replicating, persistent bacilli which may identify compounds
that could potentially shorten the treatment of TB.
2.3. Issues related to in vitro testing methodology
The issues discussed below were derived from the post-Gordon
Research Conference Workshop held on August 21, 2009 in Oxford,
UK as well as visits to GSK in Spain, NITD in Singapore, AstraZeneca
in India and Tibotec/J&J in Belgium.
2.3.1. Media and supplements
It appears that most of the pharmaceutical companies engaged
in TB drug discovery employ some version of the Middlebrook 7H
media series (Table 1), all of which contain bovine serum albumin
but these then vary with respect to the supplements utilized.
Perhaps themost important observation and illustrative example of
the effect of carbon source was the experience of NITD with
glycerol-containing media. A number of compounds identiﬁed by
NITD as hits in glycerol-containing media were subsequently found
to be both glycerol-dependent in vitro and inactive in vivo despite
S.G. Franzblau et al. / Tuberculosis 92 (2012) 453e488458adequate exposure. These compounds were later shown to inhibit
an enzyme involved in glycerol metabolism, resulting in accumu-
lation of a toxic intermediate.65 (GSK also observed an excessive
number of glycerol-dependent hits using BCG with possibly some
hits missed as well.) As glycerol is perhaps the most commonly
used carbon source for culturing M. tuberculosis in a variety of
protein-containing and protein-free media, in order to avoid
pursuing glycerol-dependent series it then behooves us to consider
using alternative carbon sources and/or to conﬁrm early on that all
hits obtained in glycerol-containing media are not in fact glycerol-
dependent.
There was little discussion of other experiences with media
component effects other than the results presented from the head-
to-head experiments conducted at University of Illinois (discussed
under head-to-head comparisons). One such result was that MICs
of INH in Middlebrook media containing commercial ADC supple-
ment were 1.8e2.1 mM, which was 6e7 higher than in all other
media compositions not using this particular supplement. Similar
MICs for INH in ADC-containing media were observed at Vertex
Pharmaceuticals.
The overall impression gained from the visits and the workshop
was that while there may have been an initial lack of appreciation
at individual institutions for the effects of media components,
especially carbon source, that this has changed based on direct
experience. In contrast, today some groups are determining MICs
in parallel with different carbon sources (such as glucose vs.
acetate) as supportive evidence that growth inhibition may be due
to inhibition of a particular target/pathway. There are efforts now
in designing assays more closely resembling in vivo situations
(looking into changing media with components that are part of
pathways of reported genes essential for in vivo growth). An
example is using both glucose and acetate as carbon sources in the
media.
Tween 80 and occasionally other non-ionic detergents are
commonly used to minimize clumping of mycobacteria during
growth. This is especially important for being able to aliquot
uniformly and for determining growth/inhibition by turbidity. Most
groups use these supplements in media used to grow the inoculum
and some retain it in the culture medium during exposure to test
compounds. Other groups, however, are concerned about potenti-
ating the activity of test compounds presumably by “artiﬁcially”
increasing the permeability of compounds and some instances
were cited of MIC differences of several orders of magnitude. There
was, however, little indication of speciﬁc compounds for which this
effect had been noted. As discussed below, the UIC comparative
studies identiﬁed the potentiating effect of Tween 80 only with RIF
while an antagonistic effect was noted with ethionamide and
ketoconazole.
There is a need for clarity regarding terminology used for
Middlebrook-based media. It is very common for investigators to
report the use of “Middlebrook 7H9” medium without indicating
which supplements are added or omitted (Table 1). It is recom-
mended that each supplement and its concentration be speciﬁed
when using the Middlebrook 7H9 broth base.
2.3.2. Readouts
The most common readouts appear to be a) ﬂuorometric or
spectrophotometric measurement of resazurin reduction, using
either the commercial Alamar Blue formulation (microplate Alamar
Blue or MABA) or puriﬁed resazurin (often referred to as REMA), b)
measurement of intracellular ATP using a commercial kit contain-
ing luciferin, luciferase and a lysing reagent, or c) measuring
turbidity at a visible wavelength between 570 and 600 nm. There
was some dissatisfaction with the signal:background when using
resazurin/Alamar Blue although it was not clear if this was relatedto spectrophotometric measurement where sensitivity is reduced
due to the spectral overlap of the oxidized resazurin with the
resorﬁn product. In a comparison of different Middlebrook-based
media (see section 2.6) using the MABA, signal:background ratios
approaching 20 were observed with media containing the OADC
supplement. At least two major companies have used measure-
ment of intracellular ATP in BCG for high throughput screening.
This appears to be a sensitive and reliable viability readout that
would likely be more widely employed if reliance on the relatively
expensive kits could be circumvented. Modern microplate spec-
trophotometers have the sensitivity to detect very low levels of
absorbance in the visible light spectrum, therefore some labs
choose to use this asmeasure of growth/inhibition. Nomentionwas
made of a problem here with signal:background although in
comparative experiments (see Section 2.6) the absorbance readout
gave an unacceptable Z0 value.
2.3.3. Protein binding
There appears to be a growing consensus that determining
functional protein binding via MIC shift is more important than just
determining percentage bound by equilibrium dialysis or similar
methods. Only one group, however, made mention of this during
our visits. Most groups use Middlebrook-based media containing
0.5% bovine serum albumin in their routine susceptibility assays
whereas the albumin content of blood is approximately 4% w/v.
Although albumin is the serum protein most commonly involved in
signiﬁcant binding of drugs, others such as alpha 1-acid glycopro-
tein, lipopeptides and globulins may also be involved. The most
common method of determining protein MIC shift is through the
use of serum supplements. In our head-to-head experiments (see
Section 2.6), we are evaluating both serum/plasma and pure
albumin.
2.3.4. Minimum bactericidal concentration (MBC)
In general most groups determineMBC by subculture onto drug-
free solid media from the same incubations used in MIC determi-
nation and determine the lowest concentration effecting either a 1
(MBC90) and/or 2 log10 (MBC99) decrease in CFU relative to that
existing prior to compound addition. No mention was made of the
use of metabolic or reporter gene CFU surrogates for MBC deter-
mination, likely because a) this is normally not a high throughput
assay, b) lack of sufﬁcient sensitivity to see a 1e2 log decrease from
the starting inoculum and c) excessive stability of some reporter
proteins.
2.3.5. NRP assays
In general, assays to detect activity against slow or non-
replicating cultures of M. tuberculosis use oxygen or nutrient limi-
tation or low pHwith or without nitric oxide. Very recently, models
have been described that use bioﬁlms66 or a streptomycin-
requiring strain,67 however, the newer assays were beyond the
scope of discussion during the visits or theworkshop. Several of the
companies we visited haveworkedwithmore than one NRPmodel,
typically at least aWayne-typemodel and a starvation or stationary
phase model. All use CFU readouts but at least one group includes
intracellular ATP as an alternate viability indicator in their Wayne
model. There was no mention of conducting high throughput
screening with an NRP assay although this would not be feasible
with CFU readouts. It is not clear how many groups examine
compound activity at low pH as this was only mentioned by one
group and in that case the liquid broth method used was the
BACTEC with the polyoxyethylene stearate (POES) supplement. RIF,
TMC-207 and pyrazinamide (PZA) are considered to be relevant
controls. Overall there is no consensus regarding the relative value
of the different NRP models.
Text box 1.
Lessons learned about in vitro assays from the workshop
and visits to laboratories
 Absorbance, redox and intracellular ATP assays most
commonly used for MIC determination
 BCG considered a useful surrogate for HTS
 Glycerol-dependent hits need to be recognized early
 Tween 80 can profoundly influence activity
 Relative value of individual NRP models uncertain
 Macrophage assay considered highly informative by
some, of no value by others and a profiling assay but
not on critical path by most
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There is general consensus regarding the need for a panel of
globally representative strains of M. tuberculosis to conﬁrm that
new drug classes would be useful against all major genetic clades
found throughout the world. Currently some institutions have
clinical isolate collections but to our knowledge none have all of the
desired attributes:
B Originate from single colonies (which has the advantage of
eliminating mixed infection, however, there is a risk of limiting
diversity by isolating only a subclone).
B Contain representatives from all major genetic clades as
determined by at least 2 typing systems
B Have full genome sequences
B Have multiple aliquots of freeze-dried stocks for long term
storage
B Complete chain of custody
B Early passage number from original clinical isolate2.3.7. Macrophage assay
Themacrophage assay is considered critical by some groups and
of little to no importance/usefulness by others. Part of this
disagreement stems from differences observed between the loca-
tion of M. tuberculosis in mouse models and in humans. However,
although the bacilli appear to bemostly intracellular inmostmouse
models, there is skepticism by some about using the macrophage
assay as a ﬁlter before testing in mice. The groups that place the
most emphasis on this model point out the importance of variables
such as passage number or cell type or (in the case of PZA) acti-
vation status and whether conditions support bacterial growth or
persistence. One group mentioned that in their laboratory in vivo-
active compounds did not always show TB activity in macrophages.
In fact, three of their most active compounds in the mouse model
did not show any activity in the macrophage model. The reason for
this was not clear, but might (at least in part) have to do with the
solubility of the compound in an in vitro system. Readout is typi-
cally CFU, although Institute Pasteur Korea uses an automated
confocal microscopy imaging system,68 and therefore can conduct
medium to high throughput screening. In general, activity in
macrophage cultures is considered a proﬁling assay that often is not
included among those on the critical path.
2.3.8. Whole blood assay
Although not discussed at the post-conference workshop
described above, the whole blood assay is essentially an intracel-
lular infection model that can be used to determine the activity of
anti-TB agents.69 This involves incubation of M. tuberculosis in
heparinized whole blood collected from drug treated individuals
(or alternatively the blood samples are ex-vivo exposed to anti-TB
agents) and subsequent determination of the viability of
M. tuberculosis by time to positivity in the BACTEC 460 or MGIT 960
systems. Interestingly the aminoglycosides, which are widely
considered inactive in macrophage monolayers, demonstrated
potent activity in this assay.70 A recent publication describes the
use of this assay to assess combinations of experimental and
established anti-TB drugs for activity against XDR-TB.71
2.4. Overview of the in vitro methodology and key deﬁnitions in the
ﬁeld
The major variations in the in vitro testing of experimental
compounds against replicating cultures include culture media
composition and readout. Culture media are usually based on a)
a deﬁned minimal media with glycerol as the carbon source anddevoid of protein (Sautons, Proskauer-Beck, Glycerolealanine-
salts), or b) albumin containing media that use fatty acids and/or
glycerol as the primary carbon source (Middlebrook or Dubos).
Either type of media may be used with or without a non-ionic
surfactant such as Tween 80 to promote dispersed growth.
Because non-CFU methods of growth determination are signif-
icantly faster and less labor intensive, they are widely used in TB
drug discovery efforts. In addition ﬂuorescent and luminescent
readouts from dye reduction or reporter gene expression offer
increased sensitivity for growth detection and in the latter case,
fewer problems with background signal from the test compounds.
There are however, few direct comparisons of different readouts
when testing compounds against M. tuberculosis.
Althoughmost non-replicatingmethods use a CFU readout, they
vary markedly with respect to the means of restricting bacterial
growth due to the culture and environmental conditions used.
Because the published methods also differ markedly with respect
to culture medium and incubation conditions, no attempt was
made to determine the impact of each variable. Instead methods
were reproduced from the existing publications with the primary
intent of determining if test compounds would be ranked similarly
in the different methods or if particular compounds would only be
active in speciﬁc assays.
2.5. Head to head comparisons of the in vitro methodology
During visits to labs involved in TB drug discovery, we discussed
numerous variables impacting primary screening, MICs, MBCs
macrophage and non-replicating assays. These included media
composition, formats, readouts, species/strains and means of
achieving a non-replicating (NRP) state. We chose to investigate all
of these except for macrophage assays and species/strains; the
latter was omitted since there was a study in progress that was
evaluating the major surrogates, M. bovis BCG and M. smegmatis.64
In addition to other media components, we also examined the
effect of serum and increased protein concentration since existing
culture media do not use protein concentrations that reﬂect
physiological concentrations. There is also a lack of information in
the literature regarding high protein concentrations.
All evaluations of the culture media composition, readouts and
protein/serum on MIC were performed using an 8 mm ﬁltered,
frozen, H37Rv ATCC 27294 inoculum at a ﬁnal density of
1e3  105 CFU/ml in 96-well format. Microplate cultures were
incubated without sealing at 37 C for 1 week and signals acquired
in a Victor-3 multilabel reader. MIC was deﬁned as the lowest
concentration effecting a reduction in signal of 90% relative to
untreated controls as determined by interpolation from the
doseeresponse curve.
Text box 2.
Key Definitions on in vitro assays
 Minimum inhibitory concentration (MIC): Minimum
concentration effecting a reduction in growth at the end
of the incubation period relative to untreated controls of
50, 90 or 99% and often indicated as an MIC50, MIC90 or
MIC99, respectively. Readouts can be cfu on solid media
or absorbance, fluorescence or luminescence of liquid
cultures. The terminology of MIC50 and MIC90 is also
routinely used in clinical microbiology to indicate the
concentration of a compound effecting a defined
percent inhibition of a percentage (50 or 90) of clinical
isolates. Therefore in order to avoid confusion it is
strongly recommended that the criteria (percent inhi-
bition) for determining the MIC of samples against
a particular strain be defined separately in a manuscript
or presentation and then indicated as MIC (only) and
not MIC50 or MIC90.
 Minimum bactericidal concentration (MBC): The
minimum concentration to reduce viability (as deter-
mined by cfu) by 90 (MBC90) or 99% (MBC99) relative to
the starting inoculum.
 Protein or serum/plasma shift: The fold increase in MIC
in the presence of a protein or serum/plasma concen-
tration that exceeds that used in the basal testing
medium. Sincemedia commonly used for susceptibility
testing ofM. tuberculosis can contain from 0 to 0.5% w/
v protein, descriptions of protein shift should indicate
the protein concentrations and protein source of both
the basal and supplemented media.
 Non-replicating M. tuberculosis (NR-TB) or non-
replicating persistent M. tuberculosis (NRP-TB): With
respect to in vitro models, this refers to culture condi-
tions that preclude a net increase in cfu during incu-
bation. Existing models utilize oxygen or nutrient
deprivation, low pH, NO or a combination of low pH/NO
to restrict growth.
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ment of tuberculosis or experimental evidence of in vitro or in vivo
activity. With a couple of exceptions, only one compound from
a chemical class was included so as to maximize chemical (and
presumably target) diversity. The compounds included isoniazid
(INH), rifampin (RIF), ethambutol (EMB), moxiﬂoxacin (MXF),Table 2
Effect of Middlebrook media formulations on signal:background (S:B) in the microplate
Media Middlebrook 7H9 broth þ bovine serum albumin supplemented with
Glycerol Palmitic acid Oleic acid Dextrose
1 (7H12) x
2 x
3 x
4 x x
5 x
6 x
7* x x
8y x x x
9y x x x
10y x x
11y x x
12* x x
13 x x
* Commercial ADC supplement.
y Commercial OADC supplement.
x From 2 to 3 independent experiments.streptomycin (SM), capreomycin (CAP), linezolid (LIZ), ethionamide
(ETH), cycloserine (CS), PA-824, TMC-207, clofazimine (CLF), clari-
thromycin (CLA), nitrofurantoin (NFT), thiacetazone (TAC), pyr-
azinamide (PZA), ketoconazole (KETO) or econazole (ECO).
2.5.1. Media composition and readouts
The Middlebrook 7H series is widely used in clinical drug
susceptibility testing (DST) and in drug discovery efforts. It is based
on a common basal medium (7H9 broth base) with a variety of
possibilities for supplementation as indicated in Table 1. The major
variations in the Middlebook media series concern the major
carbon source [typically either glycerol or oleic acid (or palmitic
acid in the case of 7H12 medium)], and the presence or absence of
non-ionic surfactants [such as Tween 80 (polysorbate 80), WR1339
or tyloxypol]. In addition, some variations include Casitone,
a casein digest. Therefore, these variations were assessed for the
effect on both signal:background and on compound MICs.
Media were broadly classiﬁed as either 7H12-based (7H9 broth
common components þ 5.6 mg/ml palmitic acid as carbon
source, Table 2: media 1e5) or 7H9-based (7H9 broth common
componentsþ glycerol and/or 50 mg/ml oleic acid as carbon source,
Table 2, media 6e13). MICs were determined using the microplate
Alamar Blue assay (MABA).
2.5.1.1. Effect of Middlebrook media components on signal:back-
ground (S:B) ratio in MABA. After one week incubation, ﬂuores-
cence measurements of cultures containing only bacteria (without
any added drugs) indicated that signal:background in general was
similar in 7H12-based media and 7H9 media containing the
commercial OADC supplement.18e20 There was a modest reduction
in media containing the ADC supplement (Table 2, media 7 and 12)
and a very signiﬁcant reduction in when Tween 80 was added to
either 7H12 or 7H9-based media (Table 2, media 3 and 13,
respectively).
2.5.1.2. Effect ofmedia components onMICs inMABA (Table 3). Tween
80 was found to signiﬁcantly potentiate the activity of RIF, con-
ﬁrming previous observations dating back to 1969.72 This was
observed in both Middlebrook-based media (Table 3) as well in
protein-free media (Table 4). It was also the only example of
a medium component decreasing the MIC of any drug. The same
supplement was found to signiﬁcantly increase the MIC of ETA and
KETO, again in both Middlebrook-based and protein-free media.
Less antagonism was (only) noted in the former media with TMC-
207 and CLF. Middlebrook media incorporating the commercialalamar blue assay (MABA).
Signal:backgroundx
Catalase Casitone Tween 80 Mean SD
x X 18.06 3.15
x 16.20 3.50
x x x 3.72 0.58
x x 18.69 2.66
x 19.20 2.34
x 16.06 4.80
x 13.35 1.51
x 19.38 3.26
x x 20.61 1.82
x x 19.01 3.20
x 21.11 2.70
x x 14.07 1.59
x x 6.61 1.65
Table 3
MABA MIC of anti-TB agents in various formulations of Middlebrook media.
Media* MIC (mM)
RIF INH ETH PA SM MXF TMC CLF CAP NFT EMB CS CLA LIZ ECO KETO
1 0.06 0.24 2.35 0.12 0.37 0.22 0.06 0.13 0.93 43.75 6.81 23.67 3.41 0.96 11.39 7.60
2 0.05 0.25 0.86 0.23 0.22 0.23 0.06 0.13 0.95 25.90 6.84 16.62 0.36 0.83 10.78 7.70
3 0.02 0.48 33.62 0.39 0.28 0.22 0.19 0.46 0.97 35.80 3.92 24.02 1.59 1.19 22.65 43.47
4 0.06 0.24 1.97 0.06 0.32 0.21 0.12 0.23 1.64 42.02 3.62 22.96 2.13 0.90 11.35 10.13
5 0.04 0.24 2.32 0.12 0.43 0.23 0.09 0.23 0.78 37.37 6.12 23.86 1.30 0.87 11.14 7.59
6 0.07 0.29 1.73 0.14 0.24 0.23 0.12 0.28 0.54 26.60 4.08 22.10 0.73 0.89 11.71 10.87
7 0.10 3.43 5.04 0.24 0.67 0.23 0.11 0.16 1.79 27.27 9.40 45.62 0.48 0.81 9.81 18.14
8 0.06 0.36 4.71 0.16 0.44 0.24 0.11 0.23 1.38 36.05 8.19 22.88 0.30 0.88 13.16 24.14
9 0.06 0.27 5.06 0.12 0.48 0.23 0.07 0.12 1.76 44.07 13.40 24.26 0.26 0.78 10.83 24.06
10 0.06 0.44 4.69 0.21 0.50 0.24 0.08 0.18 0.96 48.88 14.96 24.76 0.37 0.81 11.73 23.25
11 0.04 0.38 4.73 0.21 0.34 0.23 0.08 0.19 0.96 34.59 7.42 22.29 0.30 0.78 10.06 23.35
12 0.07 1.98 3.75 0.12 0.49 0.22 0.09 0.17 1.01 33.24 7.53 46.56 12.41 0.65 7.88 33.06
13 0.01 3.97 25.05 0.30 0.91 0.25 0.37 0.67 1.97 73.86 15.70 74.96 9.56 1.65 23.69 51.16
In bold: 4-fold vs. 7H12 medium.
In italic: 4-fold vs. 7H12 medium.
* Medium compositions in Table 2.
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versions using either the commercial OADC supplement or 7H12
media (which contains albumin, catalase and palmitic acid).
Dextrose appears to modestly increase MICs of ETH and SM in
Middlebrook-based media. MICs of EMB were signiﬁcantly
increased in all protein-free media (Table 4) compared to the
protein-containing Middlebrook-based media. Finally alanine,
present in glycerolealanine-salts medium, antagonized the activity
of CS in the protein-free media, an effect described more than 40
years ago73 that is consistent with the mechanism of action of this
drug.
2.5.1.3. Readouts. Three readouts were evaluated for MIC testing in
both 7H12 and 7H9 þ OADC media: absorbance at 570 nm, ﬂuo-
rometric measurement of Alamar Blue reduction and luminescent
measurement of intracellular ATP (Table 5). In 7H12 medium, MICs
for CLA, INH, MXF and CS were >3e4 fold higher in the ATP assay
vs. either MABA or A570 but the former assay returned a lower MIC
for CLF. MICs for both RIF and CLA in 7H9þOADC were >4-fold
higher when assessed by A570 vs. MABA or ATP. Overall the
results suggest that the measurement of intracellular ATP is a reli-
able method for determining MICs across compound classesTable 4
MIC of anti-TB agents in protein-free vs. protein-containing media.
Drug MIC (mM)
GAST Fe* GASTy Sauton þ Tw 80 Proskauer
Beck 2
7H9 w
glycerol þ ADC
RIF 0.01 0.01 0.01 0.10 0.13
INH 0.12 0.24 0.19 > 8 3.63
ETH 18.50 17.75 69.45 1.84 4.84
PA-824 0.24 0.26 0.24 0.26 0.36
SM 1.61 1.10 0.30 1.99 0.78
MXF 0.24 0.35 0.33 0.97 0.33
TMC-207 0.12 0.12 0.14 0.11 0.16
CLF 0.10 0.15 0.24 0.18 0.22
CAP 3.18 3.31 0.72 3.49 1.00
NFT 37.39 37.64 69.39 68.07 23.22
EMB 27.44 29.91 31.07 > 32 14.50
CS 91.50 88.93 23.37 47.66 65.49
CLA 1.26 3.74 1.61 2.98 1.73
LIZ 1.55 1.91 2.91 2.44 0.97
ECO 10.34 12.11 11.21 14.77 10.96
KETO 27.54 35.50 36.69 12.20 12.72
TAC 14.27 94.69 28.42 4.08 191.38
* Glycerol-alanine-salts with Tween 80 and iron.
y Glycerol-alanine-salts with Tween 80.especially when using a medium such as 7H9þOADC. Recent
results (data not shown) conducted in parallel with CFU analysis,
conﬁrmed excellent correlation between the two readouts.
2.5.2. Serum shift assays
Of those established drugs known to be signiﬁcantly bound to
serum proteins, the vast majority are bound by albumin with
a smaller proportion bound by other proteins. It is, however, the on/
off rates of protein binding that determine whether such binding
will diminish drug availability and thus activity. Experiments in
Middlebrook media conﬁrmed the historical observations that
some protein is important for growth of M. tuberculosis in media
utilizing fatty acids as the carbon source. Human serum up to 50%
and bovine and human serum albumin concentrations up to 3 and
4%, respectively, had no deleterious effect on growth (versus the
0.5% present in Middlebook-based medium) as determined by CFU
(Figure 5). However, all did show a dose-dependent attenuation of
ﬂuorescent or luminescent signal in the MABA and ATP assays,
respectively. At the highest concentrations (4% albumin or 50%
serum), after 7 days of incubation this resulted in ATP signal:-
background of approximately 150 and 51 with albumin (bovine or
human) and serum, respectively. Using the MABA, these values
were 3e4 and 2 for albumin and serum, respectively. Preliminary
drug studies with 50% human serum and 5% human albumin in
7H12 and 7H9þ OADC using MABA showed an MIC shift ofþ3-foldTable 5
Effect of readout on MIC of anti-microbial agents in Middlebrook media.
Drug MIC (mM)
7H12 7H9 þ OADC
A570 MABA ATP A570 MABA ATP
RIF 0.10 0.10 0.09 0.25 0.03 0.05
INH 0.24 0.24 0.90 0.24 0.24 0.45
PA-824 0.04 0.07 0.09 0.31 0.09 0.21
SM 0.56 0.44 0.86 0.78 0.39 0.56
MXF 0.25 0.26 0.79 0.23 0.22 0.36
TMC-207 0.07 0.07 0.05 0.14 0.06 0.20
CLF 0.27 0.28 0.08 0.41 0.18 0.32
CAP 1.02 1.02 0.89 1.57 0.59 1.39
NFT 53 42 86 79.46 33.42 51.81
EMB 2.53 2.84 7.89 8.92 7.62 15.08
CS 24 24.17 85.25 44.17 21.61 23.71
CLA 8.36 6.41 44.87 19.82 0.27 3.48
LIZ 0.90 0.73 0.93 0.96 0.64 0.97
KETO 6.20 5.97 9.00 26.10 12.00 22.29
Figure 5. Effect of serum and albumin concentration on M. tuberculosis viability (CFU), Alamar Blue-mediated ﬂuorescence and intracellular ATP-dependent luminescence.
S.G. Franzblau et al. / Tuberculosis 92 (2012) 453e488462for RIF with both protein sources (Table 6). In contrast, PA-824 had
a þ7-fold shift with serum and þ3-fold shift with albumin. SM and
EMB had þ2e3-fold shifts in serum but no shift with albumin.
Isoniazid andMXF showed noMIC shifts. Therewere no differences
between the two Middlebrook media versions. In general the
results are consistent with higher protein binding of hydrophobic
compounds. Although serum effects a larger signal attenuation
then albumin when using metabolic readouts, it contains proteins
other than albumin such as alpha 1-acid glycoprotein, lipopeptides
and globulins, which may be important in protein binding orTable 6
Effect of serum and albumin on MABA MIC of anti-TB agents in Middlebrook media.
Drug MIC (mM) using the following media:
7H12 media containing
Human serum Human albumin
0.5% 50% 0.5% 4%
RIF 0.11 0.35 0.05 0.20
INH 0.47 0.28 0.24 0.42
SM 0.50 1.53 0.38 0.50
MXF 0.41 0.24 0.39 0.46
PA-824 0.12 0.85 0.20 0.75
EMB 7.79 14.80 5.05 6.13
None, RFU* 144,882 76,441 382,737 22,2
* Net relative ﬂuorescent units.metabolism of test compounds. The ATP readout is sufﬁciently
strong to minimize the impact on signal:background and the
concurrent evaluation of both albumin and serum can provide
additional information regarding the nature of any observed
reduction in activity.
2.5.3. Non-replicating persistence assays
We compared head-to-head, selected assays utilizing hypoxia
(in both tube74 and microplate75 versions), starvation,76 stationary
phase77 and low pH/NO release.78 The methods used were taken7H9 media þ OADC containing
Human serum Human albumin
0.5% 50% 0.5% 4%
0.06 0.21 0.03 0.13
0.42 0.24 0.45 0.43
0.52 1.50 0.69 0.71
0.37 0.24 0.37 0.42
0.21 1.39 0.25 0.77
7.65 21.36 12.79 7.85
63 513,767 88,521 224,325 19,167
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NO method, additional personal communications) and used to
compare several assays for the in vitro evaluation of 12 anti-
microbial agents against slowly or non-replicating M. tuberculosis.
With the exception of the use ofM. tuberculosis H37Rv, there was no
attempt to control any single variable. All assays were evaluated
(only) by CFU and all drugs were tested at 1, 10 and 50 mg/ml
(Table 7).
In nearly all cases, dose responses were observed in all assays.
Of the few exceptions, two were observed with ethambutol (low
pH/NO and UIC low oxygen). Greater than 90% inhibition at the
highest concentration of 50 mg/ml was observed for 8e9 of the
drugs by the low oxygen assays, for 5 drugs by the low pH/NO and
stationary phase assays and for 4 drugs by the starvation assay.
The two low oxygen assays returned very similar results. At lower
concentrations the CSU assay appeared slightly more sensitive to
RIF and MXF while the UIC assay appeared more sensitive to TMC-
207, CLF and CAP and at the highest concentration, MET as well.
PZA failed to effect a 90% reduction in viability in any of the assays
with strongest activity being 72% inhibition at 50 mg/ml in the low
pH/NO assay. Considering the pH-dependence of this drug and the
relative low concentrations used in this study, perhaps this is not
surprising. Likewise EMB, as expected, failed to effect a 90%
reduction in any assay at any concentration. INH, also considered
to be an inactive “control” only demonstrated >90% inhibition in
the low oxygen assays and then only at 50 mg/ml. RIF, PA-824 and
MXF were active (>89e90% reduction in viability) in all assays at
10 mg/ml. CLF demonstrated activity in all assays at some
concentration with the exception of the starvation assay. Assays
that appeared to be uniquely sensitive to speciﬁc drugs included
the low oxygen assays (especially the UIC version) for capreomycin
and the low pH/NO (and to a lesser extent, the starvation assay)
for NTZ.
When comparing the results obtained here in a single lab vs.
published reports, in general we observed higher levels of activity
for some drugs in some assays. For example, although our data
were for themost part consistent with those previously reported by
Gergenbacher et al. for the starvation assay,76 we did see higherTable 7
Activity of antimicrobial agents against slowly or non-replicating M. tuberculosis.
>90% inhibition* @ Starvation76 Stationary77 Low
pH/NO78
Low O2
UIC75
Low O2
CSU160
1 mg/ml MXF PA-824 RIF
CLF MXF
RIF
SM
TMC-207
CAP
10 mg/ml PA-824 RIF RIF MXF TMC-207
RIF PA-824 PA-824 SM
NTZ CLF
CLF PA-824
MXF
50 mg/ml TMC-207 SM MET CAP
NTZ CLF INH INH
>50 mg/ml MXFy TMC-207 INH EMB NTZ
CLF CAP TMC-207 NTZ EMB
SM NTZ PZA PZA MET
CAP INH CAP PZA
EMB EMB SM
INH MET MET
PZA PZA EMB
MET
* All readouts are CFU.
y 87e89% inhibition at 50 and 10 mg/ml respectively.activity with TMC-207. Likewise we observed activity at lower
concentrations than those reported by Lenaerts et al. for RIF, INH,
MXF and PA-82474 although in both cases MET appeared to be
devoid of potent activity even at 50 mg/ml. Conversely we observed
less activity for RIF and INH in the stationary phase assay reported
by Sulochana et al.77
2.6. Future directions
The comparisons done here are restricted by the limited
chemical diversity and number of corresponding molecular
targets. As additional compounds with conﬁrmed mechanisms
become known, these should be evaluated in a similar manner. In
some cases, HTS with diverse chemical libraries would be very
valuable although the number of variables evaluated would need
to be limited. Newer reporters such as the mCherry ﬂuorescent
protein and luxABCDE construct may be superior to those
constructs used in M. tuberculosis reporter strains to date. The
luxABCDE codes for both luciferase and the n-decanal substrate
and so, like the ﬂuorescent reporters, does not require the addi-
tion of a substrate and enables the observation of the kinetics of
growth/inhibition.79 Preliminary data obtained in our lab with the
luxABCDE construct (provided by Siouxsie Wiles, Imperial College,
London) corroborates the utility in determining MICs and we have
recently used this construct to screen a 100,000 compound
library. The utility of this reporter however extends beyond MIC
determination to include MBCs and activity in macrophage
culture79 and we are currently evaluating its use in the low
oxygen recovery assay.75 Although the MIC protein-shift models
described above can be used with data normalization, additional
rapid readouts (e.g. ﬂuorescent protein reporters, turbidity, lux-
ABCDE reporter) or means of neutralizing the protein effects
should be assessed to lessen or eliminate signal attenuation. At
least two additional NRP models, one utilizing a streptomycin-
dependent strain67 and another resulting in formation of a bio-
ﬁlm66 have been recently reported and it would be of value to
evaluate these in head-to-head comparisons as well. The
achievement of an NRP state certainly is not unique to the H37Rv
strain, nor to theM. tuberculosis species. The recent demonstration
of M. bovis BCG having reasonably good concordance with
M. tuberculosiswith respect to the sensitivity of replicating cultures
to diverse compounds,64 suggests that a direct comparison of the
sensitivity of NRP cultures of these two species should be
conducted.
Determination of synergy or antagonism, although of obvious
interest for a disease that requires treatment with multiple drugs,
was not assessed in this study largely because there is little
evidence that existing methods are predictive of these effects
in vivo. Such determinations are most commonly performed via
checkerboards and calculation of a fractional inhibitory concen-
tration (FIC) index. The detection of synergy using this method can
only be done as sub-MIC concentrations. Alternatively these
interactions can be determined using time-kill curves where
synergy can be detected at concentrations greater than the MIC
which may be more physiologically relevant. The disadvantage is
the requirement of a CFU readout. The sensitivity and dynamic
range afforded by intracellular ATP measurements or use of the
luxABCDE reporter could make this a viable alternative readout for
kill curves.
2.7. Final recommendations
During initial screening, especially HTS, it is important to
maximize sensitivity as it is unlikely that these compounds will
ever be re-tested. From this perspective it is preferable to
Text box 3.
Lessons learned from the in vitro laboratory experiments
 Tween 80 can both potentiate and attenuate compound
activity
 Use of the OADC supplement in Middlebrook media vs.
the ADC supplement yields higher signal:background
ratios in MABA and lower MICs for some drugs.
 MICs of particular compounds can vary with different
media/readout combinations.
 50% serum or 3e4% serum albumin can be used in MIC
protein shift evaluations without compromising
viability/growth but with a dose-dependent inhibition of
fluorescent or luminescent readouts; an ATP readout
maintains a better signal:background ratio.
 The low oxygen assays demonstrate sensitivity to
a greater number of existing/experimental TB drugs
than do other non-replicating/slowly replicating assays.
While RIF, PA-824 and MXF appear highly active in all
tested assays, the relative activity of a few drugs
appears to be assay-specific.
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former can be rapidly and efﬁciently identiﬁed in a counter-
screen. Overall, it is recommended to use a medium devoid of
glycerol and Tween 80 and employing a fatty acid as the carbon
source. Simply using Middlebrook 7H9 þ OADC without any
additional supplements will give a good signal:background in
growth assays. It is likely (but not conclusively determined here)
that the dextrose and catalase components are inconsequential
and could be eliminated if the supplement is being prepared from
individual components (vs. purchasing commercial products).
Either intracellular ATP or redox-based assays are recommended.
Cost concerns aside, the intracellular ATP assay might be optimal
for HTS due to the low probability of background luminescence
with subsequent conﬁrmation by a redox dye method such as
MABA or REMA. Our experimental results suggest that using
absorbance measurements alone should be done with caution
due to a very low signal:background, however most MICs ob-
tained with this method did correspond with those obtained via
MABA.
Protein MIC shift experiments can be conducted with conﬁ-
dence at 50% serum or 3e4% albumin, however data need to be
normalized if using ﬂuorescent or luminescent readouts. Intracel-
lular ATP maintains a good signal:background while that for the
MABA (and possibly other redox-based readouts) is signiﬁcantly
reduced. Both serum and albumin can be used concurrently to
differentiate albumin-speciﬁc effects from those possibly caused by
other serum constituents. It should be noted that larger protein
shifts could likely be noted if beginning with protein-free media
(versus Middlebrook media with 0.5% BSA). Therefore, such protein
MIC shifts should be interpreted in a relative manner with respect
to a series of control compounds.
Based on the limited information available at the time of this
writing, it is difﬁcult to make speciﬁc recommendations regarding
NRP assays. We can only encourage research groups to run
multiple assays on the largest number of compounds, especially
those with known mechanisms and to report this data so as to
build up a cumulative body of knowledge. As more of these
compounds reach animal models and clinical trials and are
assessed for the ability to reduce duration of treatment, we will
slowly gain an understanding of the relevance of such in vitro
models.3. In vivo evaluations of TB drugs
Methodologies for preclinical testing of drugs against M. tuber-
culosis in animal models do vary signiﬁcantly from laboratory to
laboratory; however, it is unknown whether the heterogeneity in
the experimental parameters of thesemethods affects the results of
these studies, or can be considered an advantage. Would two
different laboratories studying the same agent or drug regimen
arrive at different conclusions regarding efﬁcacy? For instance, can
the mouse strain or strain of TB determine the outcome of drug
efﬁcacy trials? These questions are of great importance to rate the
ability of the different TB infection models to rank order new
regimens and compare them to the standard regimen for drug
susceptible TB. To begin the process of understanding the state of
affairs in a variety of academic and industry laboratories, we began
a multi-pronged approach to understand the various protocols
currently used in the ﬁeld. This included personal visits to labora-
tories, an electronic survey, a multi-national workshop and a series
of head-to-head animal model experiments in one laboratory.
The historical and contemporary methodology was identiﬁed
from the literature. Protocols and philosophies from top universi-
ties, companies and institutions engaged in TB drug discovery and
development were collected via an electronic survey and personal
visits. The survey was designed and conducted to elicit annotated,
detailed information on protocols which is generally not present in
publications. We included 95 questions with one-half appropriated
to in vitro screening and the other half to in vivo assays. Personal
visits were conducted with many TB drug development represen-
tatives to discuss screening strategies, issues and recurring prob-
lems as well as receiving recent updates on in vivo projects. The
visits, survey and literature searches then allowed us to prioritize
the questions raised regarding animal models in need of re-
evaluation in head-to-head experiments in one laboratory. In the
head-to-head animal model experiments, we compared carefully
varying key assay variables (such as strain of mouse, route of
infection, timing and formulation of drugs) in order to ascertain the
relative contribution to outcome of the animal trial. For this Drug
Accelerator grant effort by the Gates Foundation, we were
instructed to only focus on mouse models currently used in the
ﬁeld. The three most commonly used mouse models by experts in
the ﬁeld were at the start of the project; the intravenous injection
model, a low dose and a high dose aerosol infection model. We
compared results in two of the most commonly used strains of
mice. This is the ﬁrst report on side-by-side comparisons of assays
and animal models used in the ﬁeld.
3.1. Historic overview of animal models
3.1.1. Early animal models
In the development of new drugs and vaccines for
M. tuberculosis, animal models have always been a crucial compo-
nent.6,80,81 In many of the earlier studies, larger animal species such
as guinea pigs and rabbits were primarily chosen, and often studies
with high animal numbers were employed. Since the early 1900s,
animal studies for drug evaluations provided information on
histopathology, bacterial pathogenesis as well as penetration and
effect of compounds such as thiocyanate and gold.82,83 While
insight was gained mostly on the biology of the disease, most drug
therapies being evaluated at the time were usually disappointingly
ineffective against the infection.84 Many historic studies made
remarkable contributions by thoroughly detailing histopathology
of M. tuberculosis infected animals.85,86 The progression of
pathology after a TB infection in mice was beautifully described
and illustrated by Youmans in 1948.87e89 The authors mostly pre-
sented this data, consisting of the gross lung lesions (showing
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The 1930s through the 1950s brought more promise of new agents
for the treatment of tuberculosis. It was only in later studies
beginning in the late 1940s and 1960s that the emphasis shifted
from the larger animal models for TB drug evaluations to using the
mouse model for tuberculosis.87,90e94
At times the instrumentation for performing in vivo inoculations
withM. tuberculosiswas homemade, but the infection of the animal
could be observed (by gross pathology and changes in body weight)
and showed to be reproducible. Often, the infection procedure was
conducted under a laminar ﬂow cabinet with a strong updraft,
which represents an early environmental control system for
biosafety purposes. The optimization of culture and propagation
conditions of M. tuberculosis on solid agar media95,96 allowed for
the identiﬁcation of colony morphology, bacillary enumeration and
drug resistance evaluation, and therefore made it possible to use
well-deﬁned inocula for infection of the animal models. Animals
were infected via various routes of inoculation such as subcuta-
neous, intracutaneous, intravenous injections (IV), orally, intra-
peritoneally, eye inoculation, intracerebrally and aerogenically (by
aerosol, intranasal or intratracheal routes)81,90e93,97e105 The IV
route proved practically difﬁcult in guinea pigs given the paucity of
superﬁcial vessels. This method was easier in the rabbit using the
marginal ear vein, and was often performed in mice via the lateral
tail vein.92,93 The IV route allowed for a uniform deposition of the
TB bacilli in the lung via the hematogenous route.
An important era ensued when a careful evaluation and cata-
loging of M. tuberculosis strains was started around 1945 after
a meeting of the American Thoracic Society and the National
Institutes of Health (NIAID).106,107 For instance, a collection of
mycobacterial strains was established at the Trudeau sanatorium
in Saranac Lake NY in 1946, under the guidance of Dr. William
Steenken.108 For each bacterial isolate in the collection, the species
name and strain was recorded; its history and source; date of
deposition at Trudeau; its virulence patterns in mice, guinea pigs,
and rabbits if available. In addition, a series of in vitro tests were
conducted to determine growth characteristics, biochemical
proﬁle and drug susceptibility, and the data were then compared
to the properties of a ‘hypothetical median strain of TB’.107e109
Another important advance in the 1950s was the development
of in vitro culture methods that allowed enumeration of myco-
bacteria from organ homogenates as a measure for drug efﬁcacy
from animal infection studies.92,93 However, it was the discovery
of streptomycin (SM) and its subsequent successful testing in
Guinea pigs that represented a major landmark in the animal
modeling ﬁeld.110
3.1.2. The guinea pig model
The ﬁrst use of Guinea pigs in tuberculosis research was for TB
diagnostic studies that involved the inoculation of animals with
human sputum. Guinea pigs were themain animal studied by Koch,
when he ﬁrst saw and described the “Koch phenomenon” [caused
by a delayed-type hypersensitivity response] similar to that
observed in humans.111e113 The descriptive pathology was often
illustrated with highly detailed and annotated drawings of micro-
scopic images in the early days of the ﬁeld, including by Koch
himself.114 Due to its high susceptibility to intravenous and aerosol
routes of infection with the tubercle bacillus, the Guinea pig was
the favored animal model for many years especially by the Mayo
Clinic investigators.115e118 One of the ﬁrst reports of an in vivo active
compound was by Rich and Follis in the late 1930s, who tested
sulphanilamide in Guinea pigs.100 Other early studies included
testing of SM as monotherapy and in combinations with drugs such
as para-amino salycilic acid (PAS).119 In these early studies,
measures for drug efﬁcacy other than enumeration of bacterial loadin lungs were adopted, such as weight or radiography.20,21,120,121 In
addition, survival, changes in animal weight and gross necropsy
observations were used as crude measures of drug efﬁcacy.122,123
Another quantitative measure was developed by Mitchison, and
called the “Root Mean Virulence assay for Guinea pigs” [calculated
as the square root of the pathology score, divided by the survival
time in days] which related lung pathology to animal survival
times.124e127 Guinea pigs were often inoculated subcutaneously
and at times developed lesions at the site of the inoculation.
Infection of the Guinea pigs was occasionally checked by the
tuberculin sensitivity skin test to assess adequacy of infection and
this was also used as a marker of drug efﬁcacy.128
In the 1940s, more antimicrobial agents started to become
available that deterred the disease in guinea pigs (e.g. the sulpha-
nilamides). Due to this expansion of available compounds, a careful
assessment of the methodology was put forward around that time.
Variables included the animal species used, short term versus long
term treatment experiments, recording of necropsy outcomes, the
number of animals needed based on the desired study, and one
started to put forth criteria for judging an effective agent. Feldman
was the ﬁrst to establish a document in 1945 detailing a suggested
outline of laboratory procedures for testing antituberculous
substances in experimentally infected animals.98 In 1944 Salman
Waksman (who together with Albert Schatz discovered
SM122,129,130), sent SM to Feldman, who then used the drug to treat
guinea pigs after they had been infected with the TB strain
H37Rv.122 The drug worked spectacularly well and reduced
mortality and the number of lesions. An important outcome of
those studies was the development of the ﬁrst systematic scoring
system based on gross pathology in guinea pig organs
(Figure 6).115e117,119 Feldman established some basic guidelines for
the evaluation of chemotherapeutic agents, which included:
ensuring the virulence of the TB strain used, starting treatment
when the infection is well established, recording survival time and
showing evidence of histological improvement with therapy,
continuing to observe the animals post therapy and monitoring for
the emergence of drug resistance.86 Also in 1944, a Frenchman,
Chorine, who had studied leprosy in rats, injected the M. bovis
strain Ravenel into rats and treated the infected rats with nicotin-
amide (Vitamin B).131,132 Based on his positive results in rats, the
same approach was tried in guinea pigs infected via a subcutaneous
injection with M. tuberculosis, and noted a reduction in dissemi-
nation of the disease with derivatives of Vitamin B and this was
seen by others as well.25,133e135
Many compounds tested, such as PAS, streptovaricin (SV) and
capreomycin (CM), demonstrated activity with a clear dose-
dependent response in Guinea pigs (as well as in mice), which
was reﬂected in improvement of gross lesion involvement of lungs,
livers, spleens and at the site of inoculation.118,119,136 The readout
methodwhich combined gross lung lesion observation and survival
time proved useful to compare relative efﬁcacy among single drugs
and drug combinations. Such gross necropsy endpoints were
replaced with a quantitative evaluation of the reduction in bacterial
load and the use of amicrobial enumeration technique only became
amore common practice in the 1950se1960s in mouse models.90,91
Although the investigator Gardner Middlebrook is best
remembered for assembling the composition of 7H9 and 7H10
media for mycobacterial growth,23,101,137 he also performed several
classical guinea pig studies optimizing several delivery methods of
infection in order to investigate TB pathogenesis, drug evaluations,
as well as skin testing. In addition, he made an important contri-
bution to the animal model ﬁeld by designing the ﬁrst, of what
ultimately became awidely used, aerosol infection apparatus.138,139
In the 1950s and 1960s, the mouse model for tuberculosis became
more common likely due to practical and economic considerations.
Figure 6. Schematic of disease involvement in lungs, site of injection, spleen liver of guinea pigs infected by injection of M. tuberculosis in suprasternal notch and treated with
streptovaricin (SV) (lower panel) or untreated (upper panel). Diagram of gross pathologic ﬁndings and date of death observed in guinea pigs treated with anti-tuberculosis test
agent SV. The black dots indicate lesions visible on necropsy and the number under each animal was the number of days since infection at animal death. The solid bar under the
number indicates the number of days the animal survived. In liver, spleen, lungs the degree of involvement is indicated by the number and intensity of lesions. Death of the animal is
indicated by a black horizontal bar and the day below (illustration reproduced from the original reference119).
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Mice were ﬁrst used in the TB ﬁeld mainly to study the host
immune defense of a tuberculosis infection and to understand the
possible role of the reticulo-endothelial system in resistance to a TB
(or M. bovis) infection. In the 1940s, a more thorough analysis was
reported including the details of the mouse infection protocols, on
the susceptibility of mice to infection87e89 and important differ-
ences in pathology between mice, guinea pigs and humans were
described.140e142 Investigators like Dickinson, Mitchison and
Grosset and their colleagues did much of the pioneering work in TB
drug testing using the mouse model.143e145 Mouse studies in the
1950s and 1960s were mostly employed to test the drug effec-
tiveness by means of both lengthening of survival time and
improvement of histopathology, which then resulted in the ability
to rank active compounds.145 In most studies, the drugs were
administered tomice by administration in the diet or by injection at
a ﬁxed, high dosage. Often little pharmacokinetic information wasavailable to allow for analysis of proper drug exposure. A major
contribution in the mouse model ﬁeld was made by Mitchison and
his colleagues, who demonstrated in the 1970s that mouse data
evaluating drug regimens based on isoniazid (H, INH), rifampin
(R, RIF) and pyrazinamide (Z, PZA) were very consistent in pre-
dicting the human clinical trial results of the British Council [using
the outbred ICR mouse IV model146]. In the 1950e60s, Canetti,
Grumbach and Grosset carried out numerous large scale mouse
experiments (often containing over 100 animals infected intrave-
nously with high inocula of M. tuberculosis H37Rv) which helped
understand the role of anti-tuberculosis agents in the course of
successful therapy andmoldedmodern day chemotherapy.143,147,148
Most early studies were performed with outbred mice such as ICR,
albino or whitemice and the use of inbred strains of mice in TB drug
development is relatively new (during the last decades).
Another era started with addressing the issue of relapse of
infection after termination of drug treatment with the important
Table 8
Ranking of TB drug regimens based on relative activity during the ‘bactericidal phase
of infection’ versus the relative activity during the ‘relapse of infection phase’. Rank
order of various TB treatment regimens determined by log10 CFU in lungs of mice.
Relapse is deﬁned as the number of mice with positive organ cultures three months
after discontinuation of therapy. R ¼ rifampin, J ¼ TMC-207, P ¼ rifapentine,
M ¼ MXF, Z ¼ pyrazinamide, H ¼ isoniazid.
Regimen Rank order bactericidal activity Rank order relapse
JZP 1 1
JZPM 1 1
J1/2ZP 1 2
PZM 2 3
JZM 1 4
HRZ 3 5
Data comparison from Andries et al.166
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sity in the 1950s. McCune et al. published a key series of papers
detailing the microbial enumeration technique, and a well-
documented analysis of microbial persistence after drug treat-
ment.92,93,149,150 McCune performed many long term drug treat-
ment trials using large numbers [hundreds] of mice as well as
guinea pigs which were pivotal to form the understanding of the
‘non-culturable’ TB bacillary population after drug treatment that
can reactivate after termination of drug treatment. It became an
appreciated fact that despite persisting in the face of drug therapy,
these bacilli were susceptible to antimicrobials when tested
in vitro.92 Relapse of infection in the animals was either sponta-
neous after completion of the drug regimen (usually 90 days) or
by immunosuppression of the host. If no re-growth of bacteria
was observed in lungs and spleens upon immunosuppression, it
was concluded that the drug regimen was truly “sterilizing”.
This mouse model is mostly referred to as the ‘Cornell model’,
named after the institute where McCune made his discoveries.
Many of the methods described in his comprehensive publications
are still in use today, such as the intravenous challenge, macro-
scopic lesion analysis scoring, histopathologic assessments, and
propagation of M. tuberculosis through mouse passage to maintain
virulence.
The predictive value of mouse models for clinical trials has
been studied but also questioned throughout history. Most
experimental infection models of tuberculosis in mice have been
of great help in the development of chemotherapy for human
infection. The long-term mouse model, developed ﬁrst at Cornell
University, then at the Pasteur Institute in Paris, led directly in
1970 to the testing of the drug combination of RIF and PZA in one
of the most important of the British Medical Research Council
randomized clinical trials.151 In addition, the mouse model was
also highly predictive in showing the poor sterilizing activity of
INH and SM.143,147
Based on an editorial by Dr. D. Mitchison,152 there also have
been occasions where mouse studies might have misdirected
human clinical trials, such as in the case of (1) substituting mox-
iﬂoxacin for isoniazid in the standard drug regimen and (2) the
use of PZA and RIF for treatment for a latent TB infection (LTBI).
The mouse studies that may have misdirected human clinical trials
arose from experiments comparing the substitution of moxi-
ﬂoxacin for the main drugs (INH, EMB) in the standard TB
regimen.153,154 The moxiﬂoxacin-containing regimens were found
to be superior in mice when substituting MXF for INH. In the
particular mouse model used, the removal of INH from INH-RIF-
PZA resulted in a more effective two drug combination of RIF-
PZA suggesting an antagonism between INH and the combina-
tion of RIF-PZA in the mouse model used.155 Therefore the supe-
rior efﬁcacy seen in the moxiﬂoxacin-containing regimens in the
mouse model used was mainly caused by removal of INH and not
by adding moxiﬂoxacin as was also later shown in mice and
published.156 There was also suggestive evidence at that time that
showed the ﬁnding of antagonism to be due to incomplete
absorption of drugs in the mouse in combination treatment. These
studies in mice indicated that RIF serum concentrations were
lower when RIF was given with INH and PZA than with PZA
alone.155 We will show in a later section that the antagonism
between INH, RIF and PZA is in fact not a general phenomenon and
only seen with one speciﬁc M. tuberculosis strain. Antagonism in
the standard TB drug regimen was never observed in any of our
mouse model experiments (see Section 2.7: Head to head
comparisons of methodologies).
Although the editorial by Mitchison152 mentions that the
mouse model ﬁndings have led perhaps to a premature use of
the RIF and PZA combination in trials of preventive therapy, thisstatement is only partially correct and requires some explana-
tion. RZ did not fail as an LTBI regimen due to a lack of efﬁcacy.
The combination is highly efﬁcacious in patients but failed
because of toxicity issues.157,158 The mouse models have yielded
good results in ranking LTBI regimens on the basis of efﬁcacy
and relative duration of treatment needed to cure LTBI,159
although clinical successes for LTBI are difﬁcult to determine.
The only way the mouse was poor in predicting the clinical
outcome for RIF-PZA in LTBI is that it did not predict in early
mouse models the severe hepatotoxicity observed in latently
infected people. These reports of fatal and severe liver injury
associated with RIF-PZA treatment regimens for LTBI prompted
a later study of liver enzyme levels in mouse models after high
drug exposures.160 After high doses of RIF and PZA, a highly
signiﬁcant increase of three liver enzymes was also observed in
uninfected and M. tuberculosis infected mice.160 The mouse
model might have potential to assess hepatoxicity following
extensive exposure to tuberculosis drugs, however, this still
would need further evaluation using more comparative TB drug
regimens.
A few important papers were recently published addressing the
importance of including relapse studies in TB drug devel-
opment161e164 and on genetic variability in the M. tuberculosis
H37Rv strain,165 urging investigators to be careful in preclinical
studies, and in translating animal model data to humans. A recent
paper showed that bactericidal activity of TMC-207-containing
drug regimens did not necessarily predict sterilizing activity166
(Table 8), indicating that such relapse studies are critical to assess
the sterilizing properties of drug regimens prior to going to clinical
trials. Both of these topics are highly relevant and will therefore be
addressed in more detail later (Section 2.6: Lessons learned and
future directions). One important caveat that cannot be modeled in
the classical mouse is the advanced pathology features seen in TB
patients.
The recent observation that C3HeB/FeJ mice develop necrotic
granulomas in response to M. tuberculosis infection has raised
hopes that this strain may offer more human-like pathology.167e169
The development of necrotic granulomas is determined by
a susceptibility allele in the sst1 locus which leads infected
macrophages down a necrotic, as opposed to apoptotic, cell death
pathway.170 The lesions exhibit central necrosis and hypoxia char-
acteristic of other larger species, including humans.168 Although
there has been little work characterizing the response to antibiotics
in this species, several signiﬁcant efforts are currently
underway.168,169,171
In summary, while keeping in mind that they are only “models”,
mice have been highly instrumental in guiding TB drug develop-
ment and represent the only animal model that has been validated
to date by testing regimens and treatment durations known to
work in patients.
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Other animal species studied for tuberculosis infections in
earlier studies by different investigators often included hamsters,
rabbits, rats, voles, chick embryos, and more.100,172 Despite the
track record of the mouse model, the lack of pathological hall-
marks of human TB such as caseating granulomas, cavitary
disease, and ﬁbrosis is a known limitation of this model.6,81 Unlike
the mouse, other larger animal models such as guinea pigs, rats,
rabbits and non-human primates develop necrosis, ﬁbrosis,
mineralization and, in the case of rabbits and non-human
primates, cavitary disease.173 Bacterial persistence has been
hypothesized to result, at least in part, from environmental
conditions such as hypoxia and nutrient deprivation, as well as
reduced penetration or diffusion of drugs into lesions. The mouse
model may not entirely represent these speciﬁc environments
which might be required to assess the sterilizing activity of a new
TB drug or combination.6,81 In addition, the most widely used
mouse strains only develop inﬂammatory, but non-necrotic, lesion
types in the lungs where the bacilli reside primarily intracellu-
larly.174 This is not what is observed in progressive disease in other
animal models,174 nor in advanced human TB in which the vast
majority of bacilli are extracellular inside necrotic lesions and the
liquefactive core of cavities.175
These limitations of the mouse model are largely theoretical at
this point, as bacterial persistence is in fact a phenomenon also
observed in mice. Drug treatment in mice is highly effective in
the ﬁrst weeks of treatment but is far less effective to eradicate
the last 1% of bacilli. This results in a biphasic killing curve, and
ultimately it takes just as long to cure a mouse infected with TB
as it takes to cure a TB patient.176 No other animal model has
been validated as thoroughly as the mouse up to date, or has
demonstrated to give similar or a better prediction of drug
regimens being evaluated for clinical use. More comparative
studies using various animal models are urgently needed to
evaluate whether they show sufﬁcient superior predictive value
to justify the excess cost of using the larger animal models. The
availability of several promising new drugs and regimens
currently in clinical trials is the ideal time for these comparative
studies. In the section below, a selection of different animal
models currently being studied by investigators are listed with
their strengths and weaknesses, as well as their potential
promise in future trials evaluating new regimens. More recently,
zebra ﬁsh,177 minipigs,178 the Kramnik mouse model169,170 non-
human primates and macaques173,179 have entered the ﬁeld of
animal models for tuberculosis.
Rabbits have been used for testing drugs, but the inoculation
methods used in the past (e.g. including injection into the eye)
would likely not be permitted today. Lurie extensively studied
the rabbit model and used inbred strains of New Zealand White
(NZW) rabbits with different susceptibilities to virulent
M. tuberculosis (H37Rv or the bovine Ravenel strain).180 These
particular NZW rabbit strains became extinct, but inbred rabbit
strains which are more susceptible compared to outbred animals
have been raised again and show lung pathology closely
resembling that seen in humans.181 Rabbits are highly suscep-
tible to virulent strains of M. bovis (e.g., the Ravenel strain),
rapidly developing caseation necrosis and pulmonary cavities
and dying within 5e6 weeks of infection. In contrast, infection
with laboratory strains of M. tuberculosis, such as H37Rv and
Erdman, does not result in a productive infection, giving rise to
only 1 granuloma per 50-200 bacilli, depending on the strain
used.182e184 More recently, however, the more virulent
M. tuberculosis HN878 strain has been shown to cause a produc-
tive, robust infection reaching more than 6 log10 CFU in the lungs
after a nose-only inoculation with 1000 CFU.185 Bronchoscopicinstillation or transthoracic injection of M. tuberculosis into
previously sensitized rabbits may promote more rapid and
consistent cavitation.186,187 Despite the characteristic pathology,
the high expense of maintaining rabbits is an obstacle to their
use. Additional drawbacks include pathogen containment
concerns, since rabbits shed M. tuberculosis in the urine, and
intercurrent infections such as with Pasteurella and Bordetella
bronchiseptica [the latter also seen in guinea pigs]. However,
rabbits show to be well suited for evaluating drug distribution,
penetration and cellular accumulation in different lesion types,
using high sensitivity MALDI-MRM-MS technology as was
recently described.188e190
Rats are primarily used in drug development for pharmacoki-
netic testing of new compounds but have also been used as well in
the past for therapeutic trials for drug testing against
M. tuberculosis. Studies in the 1920s with “albino rats” found that
far higher inocula of TB were needed to kill rats compared to
guinea pigs. As a result, rats were considered resistant to a tuber-
culosis infection,98 and by implication, not suitable for research.
Most recently, NITD has developed a Wistar rat model in which
rats are infected via the endotracheal route. Bacterial multiplica-
tion follows for the next 2e3 weeks, but the onset of adaptive
immunity is associated with progressive clearance of
M. tuberculosis H37Rv.191 This spontaneous clearance of infection
makes evaluation of regimens for active TB challenging but offers
prospects for a latent TB infection model. The cotton rat has
resurfaced as a model for TB drug testing,192 as well as other rat
strains.193e195
Non-human primates are much more closely aligned to
humans and have obvious advantages in mimicking the pathology
of a human infection.196 At present, the non-human primate
model can most closely represent a naturally occurring latent TB
infection. Macaques are highly susceptible to M. tuberculosis and
can also be infected with SIV, which makes them an attractive
model for TB-HIV co-infection studies.197 Although there are
multiple difﬁculties associated with the use of non-human
primates [low availability, cost, ethical concerns], the model has
been used for TB drug testing and has renewed interest given the
similar pathology to human infection.105,179,198 Cynomolgus
macaques infected with M. tuberculosis via bronchoscopic instil-
lation of few bacilli can be followed by tuberculin skin testing and
serial clinical, laboratory and radiographic examinations to iden-
tify those developing active TB or latent infection (which occur in
roughly equal proportions). To date, however, these endpoints
have not been shown to be useful in discriminating between
highly active drug treatment regimens with differing potency. An
evaluation of the activity of metronidazole, alone and in combi-
nation with ﬁrst-line drugs is ongoing. Marmosets develop similar
pathology as macaques in response toM. tuberculosis infection, but
are smaller in size and therefore more economical. As of late, the
interest for the marmoset model has increased for their use in
transmission experiments, as they have the advantage of frequent
twinning which provides ideal control groups. Although NHPs
remain very expensive and are limited in supply, they may be best
employed to answer deﬁned scientiﬁc questions related to
microbial persistence, prevention of transmission or sterilizing
activity of selected new agents as well as biomarker research. The
use of animals in tuberculosis research changed dramatically in
the past hundred years. Due to extensive research and analysis
a greater understanding of the immunology, pharmacology,
treatment responses and pathology has been elucidated. This
effort focuses primarily on the mouse model which will likely
remain the main animal model in TB Drug development for now
due to its low requirement for drug material, economic advantages
and ease of use.
Figure 7. Survey responses regarding the animal species used for the evaluation of TB
compounds in vivo (presented in percentages). Survey question: Which animal species
is being used in your laboratory for TB drug evaluations?
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3.2.1. Survey results: overview
A ninety ﬁve question survey of protocols and opinions was
conducted of which about half of the questions were devoted to
in vitro and the other half to in vivo methodologies. The survey can
be viewed in its entirety at the following website: www.mrl.
colostate.edu/acceleration.
3.2.2. Toxicology and pharmacology
About half of the responders mentioned the use of in vitro
cytotoxicity assays. The pharmaceutical industry uses a wider array
of cell lines compared to academia. For instance one laboratory
evaluates compounds typically against a panel of 4 different cell
lines: THP-1 (human monocyte cell line, suspension), BHK21
(Syrian Golden hamster kidney cells, adherent), HepG2 (Human
Liver Carcinoma, adherent) and C6 Glioma (Rat brain glioma,
adherent), all acquired from ATCC. In addition, the industry has
easy access to additional toxicity assays and will therefore also
implement these sooner in the screening process, such as geno-
toxicity (Ames test) and cardiotoxicity (hERG binding and patch
clamp) assays. Extensive in vivo toxicology is usually not performed
at the stage of early compound optimization, but most investigators
perform an acute in vivo toxicity study with any new compound to
screen for any adverse effects (behavior, weight, food intake) and
gross necropsy ﬁndings (liver, spleen, kidney pathology analysis)
after single or multiple dose administration. A few laboratories
administer new compounds for toxicity testing for one week to
evaluate weight loss, at higher than anticipated concentrations
than those used in efﬁcacy studies. In other laboratories, acute and
chronic Maximum Tolerated Dose studies are performed before any
in vivo studies are initiated.
Before testing the efﬁcacy of an experimental compound
in vivo, most investigators evaluate its oral bioavailability to
a lesser or greater extent depending on the laboratories involved.
Usually the pharmaceutical industry, who has access to a formu-
lation and pharmacology department, performs extensive
absorption, distribution, metabolism and elimination (ADME) and
PK analysis prior to any efﬁcacy testing of novel compounds. For
the industry ADME and PK analyses of experimental compounds
are the key elements of the in vivo approach, and only important
leads will advance to in vivo efﬁcacy testing. Other institutions and
academic groups include a more basic evaluation of oral
bioavailability where the analysis of drug levels is performed by
bioassay or by HPLC. In academic settings, compounds generally
tend to advance more rapidly to in vivo efﬁcacy testing models due
to the lack of access to ADME and PK capabilities. Before any long
term efﬁcacy mouse study is initiated a more formal pharmaco-
kinetics analysis is performed by most investigators to establish
the appropriate dose and dosing schedule, aiming to achieve an
equivalent dose compared to humans for known TB drugs or drug
classes. One laboratory reported routine pharmacological assess-
ment of 6e8 time points following single doses or after steady-
state dosing, obtaining serum or plasma by cardiac puncture
using 3 mice per time point, and this laboratory also mentioned
obtaining data on bioequivalence for ﬁrst-line drugs and some
second-line drugs. Based on the in vivo PK data, the investigators
reported using non-compartmental analysis such as WinNonLin
software to calculate the PK parameters and provide a simulation
of a range of drug doses and dosing schedule. PK indices (AUC/
MIC, Cmax/MIC, T > MIC) are then determined at each dose in
order to select doses expected to be efﬁcacious in the infection
model. Some investigators described extensive pharmacokinetic
analyses using combination drug studies to rule out signiﬁcant PK
drug interactions. In another laboratory, a maximum tolerateddose (MTD) and PK/PD assays of all compounds are performed
before initiating any efﬁcacy animal studies.
Most respondents do not routinely test the ADME proﬁle of
experimental compounds in early stages of lead development. In
most laboratories, the following assays are used at some point in
the lead optimization process: the solubility of the compounds
between pH 1.0-6.8, the parallel artiﬁcial membrane permeability
(PAMPA) assay, CaCO2 assay (to assess the permeability and efﬂux),
liver microsomal assays using mouse and human microsomes (to
evaluate metabolic stability), and CYP450 inhibition. At a late pre-
clinical stage, more extensive PK studies under good laboratory
practices (GLP) conditions are conducted in rats and one non-
rodent species, which can include tissue distribution studies with
radio-labeled compounds. Drug formulation studies are also re-
ported to be initiated only later in preclinical development, after
a lead compound has been identiﬁed.
As mentioned before, this document will primarily focus on the
in vitro and in vivomethodologies speciﬁc for the testing of activity
against M. tuberculosis and less on methodologies that are utilized
in drug development in general (such as ADME, pharmacokinetics,
toxicology, formulation optimization).
3.2.3. Choice of the mouse infection model for M. tuberculosis for
drug testing
Most investigators performing in vivo studies reported using the
mouse model. About equal numbers of investigators use either
Balb/c or C57BL/6 mice (15e18%) and 11% used the outbred Swiss
mice for in vivo efﬁcacy trials. Only 4 laboratories reported the use
of guinea pigs for drug evaluations (Figure 7). The mouse model for
efﬁcacy testing of experimental compounds was favored by most
investigators because it is economical, widely available and mice
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for in vivo toxicity studies on lead compounds. One group of
investigators mentioned some disadvantages of outbredmice (such
as Swiss mice): the higher variability in CFU counts, requiring
a higher number of animals to reach sufﬁcient statistical power. In
addition, the Swiss mice grow larger and therefore the model
requires larger amounts of compound. The outbred nature of the
Swiss mice, however, was seen by a few investigators as an
advantage by reﬂecting better the diversity also seen in the TB
patient population, as well as the wealth of data available from past
studies. The advantage of using inbred mice is that results show
small variations within animal groups and will strengthen the
statistical power of the study.We have tomention here that a head-
to-head comparison was in fact never performed to study the
variance of infection between inbred and outbred mice. However,
when comparing results from published studies on Swiss mice
infected via the IV route versus our results on Balb/c mice infected
via the IV route, we see a slight trend of higher variances in the
Swiss mouse results (A. Lenaerts, unpublished observations). The
survey reported mouse strain differences, for instance the Balb/c
mice do not control the infection to the extent seen in C57BL/6
mice. Balb/c mice develop a productive infection with stable
plateau in bacterial loads in lungs and spleens as opposed to
declining bacterial numbers after initiation of the adaptive immune
response as is seen in other inbred, more resistant mouse strains
(such as C57BL/6mice). The characteristics of the Balb/c were felt to
be similar to the Swiss mice, which are less expensive and are
outbred. It was commented that C57BL/6 mice aremore sensitive to
adverse effects seen by some drugs than other mouse strains. The
main disadvantage of the mouse model was reported to be the lack
of lung pathology seen in typical human TB pathology, as reported
by several investigators. In addition, pharmacokinetics and drug
metabolism in rodents are different from humans and cross species
bridging studies/calculations have to be performed. The currently
used mouse strains may not allow observation of the full range of
alternative physiological states of bacilli present in human TB, such
as in latency. In most cases, mice harbor mainly intracellular
organisms. One investigator in the survey reported that the aerosol
infection of a susceptible animal species (such as the guinea pig)
mimics human granuloma formation, which is useful for studying
extrapulmonary dissemination and hematogenous reseeding of the
lung, and allows the evaluation of drug effects under conditions
relevant to man.
When conducting animal models for efﬁcacy testing of
compounds, the route of infection as well as the start inoculum of
M. tuberculosis differed signiﬁcantly across the different research
groups. Regarding the route of infection, the aerosol infection was
mentioned by several groups as themost realistic mode of infection
when compared to natural infection, and the guinea pig was found
by several of the responding investigators to be most reﬂective of
the human pathology and disease. At least one group uses the
intranasal route of infection for mice which is felt to at least
partially mimic the natural infection. Others pointed to the
lymphatic and hematogeneous dissemination of TB bacilli from the
lesion in favor of infecting via the intravenous route of inoculation
in the IV infection model.
The infection inocula ofM. tuberculosis reported by the different
research groups ranged from 10 to 20 CFU per animal (guinea pigs)
to more than 7 logs (intravenous injection in mice). Most investi-
gators use either an aerosol or intranasal infection with
100e3500 CFU per animal, and only a few investigators reported
use of the intravenous infection with a high bacterial number. One
group using the intranasal inoculation deﬁned their model as a low
dose infection model, because the chosen inoculum had been
shown to be the minimal dose capable of establishing a lunginfection. The investigators pointed out that when using a very low
inoculum that the bacteria are cleared before reaching the lungs, as
was indicated by an increase in the standard deviation when less
than 500 bacteria were used. Some laboratories aim at inoculating
with 10 CFU during an aerosol challenge, others prefer 200e300
CFU/mouse for drug testing purposes because the bacteria grow
faster to higher titers in the lung and spleen. The use of an even
higher inoculum (3.5e4 logs) implanted by an aerosol infectionwas
felt to be important by one group in order to reach a bacterial
burden of 7e8 logs (which is hypothesized to be similar to
a human cavity) at the start of the combination therapy 14 days
later. In this latter model, it takes approximately 6 months of
treatment with the standard HRZ-based regimen to sterilize most
mice, which is similar to the length of treatment used in TB
patients. The intravenous route where the early bacterial number is
high also allows for the extrapolation of the antibiotic treatment
results to the treatment schedule in TB patients. Investigators
stated that the IV route is a more difﬁcult technique to perform
compared to an aerosol infection. For safety considerations, the
intravenous route was aborted by at least one laboratory. It was
pointed out that often the particular method of the mouse infection
model depends whether a compound is an early hit or in the lead
optimization stage of TB drug development. For instance, a low-
dose aerosol is highly relevant for use in monotherapy trials as it
will not give rise to emergence of resistance, and it will better
represent a chronic, established TB infection. Two thirds of labo-
ratories include a placebo gavage group and most have not
observed any adverse outcomes of the placebo. Almost all labora-
tories include INH or RIF as control compounds in every study, and
all mention having good reproducibility of the results in their
validated mouse infection model.
3.2.4. Choice and propagation of the TB strain for use in vivo
In the survey, a high variability was reported for the origin and
propagation of the M. tuberculosis strains used for in vivo experi-
ments. The origin of M. tuberculosis strains in many of the labora-
tories is not entirely clear (many report the strain being a gift from
colleagues in the past) and in 40% of the laboratories there was no
record kept regarding the passage number for their M. tuberculosis
strain. Only one laboratory has compared the infectivity of their
M. tuberculosis strains and found that M. tuberculosis Erdman was
more virulent than M. tuberculosis H37Rv in guinea pigs and mice.
One reported propagation method was as follows; the
M. tuberculosisH37Rv strainwas obtained from ATCC, then grown to
mid-log phase in liquid culture, homogenized, sonicated brieﬂy,
and ﬁltered to obtain a single-cell suspension before freezing at
80 C and enumerating the bacterial number from a thawed
aliquot. A second laboratory also mentioned ﬁltering their bacterial
suspensions through a 5 micron syringe ﬁlter. One laboratory uses
an early passage number of M. tuberculosis Erdman from ATCC
grown as a pellicle and frozen as seed stocks. The seed stock is then
expanded over three passages to 100e200 ml cultures in Proskauer
Beck, up to an optical density (OD) of 0.5e0.7, and subsequently
aliquoted followed by a virulence test in mice. Others mentioned to
passage their strain in mice, then sub-culture and freeze. In another
laboratory, M. tuberculosis is grown to an OD600 of 0.3e0.5 in 7H9-
ADS medium, subsequently the cells are harvested by centrifuga-
tion (10 min, 3300 rpm), washed once in 7H9 medium at 37 C,
resuspended to obtain an OD600 of 1.0 in 7H9-ADS medium sup-
plemented with 15% glycerol, and frozen at 80 C. The viable
bacterial number of each batch is determined by plating, and before
infection, a vial is thawed, diluted and sonicated (25 s in a soni-
catingwater bath). The followingmediawere used to propagate the
bacterial culture: 1) Dubos broth with ADCC enrichment, 2) 7H9,
without Tween80, 3) 7H9-ADC media with glycerol and 0.05%
Figure 8. Survey responses regarding the type of additional or supportive readouts
used for the evaluation of TB compounds in animal models (presented in percentages).
Survey question: Are other readouts used to conﬁrm or supplement the CFU data?
Text box 4.
Lessons learned from the survey on in vivo models
 Numerous laboratories are willing to collaborate and
share ideas, challenges and protocols
 There is often uncertainty regarding the origin, history
and propagation records of the TB strain used in vivo
 Infection methods of animals vary from laboratory to
laboratory, with the inhalation method currently being
the most widely used
 Only in rare occasions were there unexpected results
reported for the mouse efficacy trials
 Mice are the species most commonly used for TB drug
testing (although our survey may have underrepre-
sented other animal models due to the focus of this
effort on mouse models)
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medium containing 0.05% Tween80, or 6) 7H9 broth with 0.02%
Tween80.
In 80% of the laboratories, frozen bacterial stocks are prepared
for the inoculation of themice (typically in 7H9) and stored in small
aliquots at 80 C for several years. This method allows a precise
duplication of the infection level of mice every time an experiment
is performed, and there appears to be no detectable change in
infectivity or virulence over many months to a couple of years.
Some investigators report to have noticed a drop in the viability
after prolonged storage at 80 C (e.g. 3e4 years), while others
found that freezing the inoculum does not adversely affect the
viability (with remarkable reproducibility of this method over
decades). The titers of frozen stocks are by most laboratories
conﬁrmed by plate counts and the virulence is evaluated in mouse
models. Others favor infecting with an actively growing
M. tuberculosis culture, and one group standardizes the inoculum
according to McFarland suspensions. It was reported that when
a fresh culture is used the optical density determinations are not
always reliable due to clumping of bacteria.
A wide range of survey responses were obtained on questions
relating to control measures on the infectivity of bacterial stocks.
One of the investigators mentioned not to enumerate bacterial
loads in the lung the day after infection in most routine experi-
ments unless the challenge strain changes, and another group
agreed with this notion as long as clumps are removed by ﬁltration.
Still, most investigators perform all appropriate controls to track
the bacterial loads in the mice at the day of infection or one day
after and at the start of treatment, and multiple responders stated
that they use a minimum of 5 mice at each sacriﬁce time point
including for control groups.
3.2.5. Readouts for drug efﬁcacy
The most widely used method for determining drug efﬁcacy in
mice remains enumeration of the bacterial load in lungs and
spleens, by counting the colony forming units (CFU) of the organ
homogenates on agar plates. For the testing of single compounds as
well as short term mouse experiments, some investigators
mentioned plating whole lungs while others plate the homogenate
of a single lung lobe from each animal. After long treatment regi-
mens when low bacterial numbers are expected, generally the
whole lung is homogenized and a sizeable fraction of up to one-half
of the homogenate is plated. One group homogenizes whole lungs
in a total of 2.5 ml PBS and then plates the entire homogenate on
ﬁve 7H11 plates (0.5 ml per plate). Another group uses whole lungs
and total spleen homogenized in 4 ml PBS supplemented with
0.05% Triton X-100. Only a minority of investigators saves organs
for histopathology, and of these, most used formalin ﬁxation from 2
to 10 days to decontaminate the histology samples. Other readout
methods besides CFU enumeration are only occasionally used in
efﬁcacy trials (pathology in 15% of the institutions, gross necropsy
in 22%, Ziehl-Neelsen staining in 15% and only one laboratory uses
auramine rhodamine staining) (Figure 8).
Relapse experiments have currently been performed by only
a few of the respondents, and the time periods allowed for relapse
vary from 12 to 40 weeks following cessation of the drug regimen.
The relapse studies are at times performed with immunosuppres-
sion (using hydrocortisone, dexamethasone or cyclophosphamide),
but aremostly performedwithout. Readouts for relapse of infection
include observation of clinical signs, CFU enumeration, histopa-
thology, spleen weights, and gross necropsy observation of lung
lesions.
All respondents use statistical methods in conjunction with
their animal trials and most do not consult with a statistician.
Treatment effects are mostly analyzed by a one-way ANOVA,followed by a T-test, Tukey or Dunnett’s test. For relapse studies
a Fisher Exact or Chi-square test is applied to compare relapse
proportions between groups.
There were some unexpected data from animal studies
mentioned in the survey. One investigator mentioned that while
metronidazole and PZA demonstrated activity in some laboratories
in mice, these drugs were not found effective in other laboratories.
Some groups observed antagonism between the three standard
drugs INH, RIF and PZA when administered in combination, while
this was not seen by other researchers.3.3. Issues related to in vivo testing methodology
The current views on in vivo testing methodologies as well as
issues in the ﬁeld are the result of a series of visits to both academic
and industry laboratories, as well from a TB Drug Accelerator
Workshop on “Assay Standardization”, which was held after the
Gordon Research Conference on Tuberculosis Drug Development
titled ‘Targets, Technologies and Trials’, in the summer of 2009 in
Oxford, UK. Since the time of the visits, however, we learned about
the fact that more groups became involved in TB Drug develop-
ment which unfortunately due to constraints of time and resources
could not be included in this document. These current views on
in vivo testing methodologies together with its issues were then
used as a starting point for the head-to-head studies described in
Section 2.5.
3.3.1. The relevance of the mouse model
The discussion during the Workshop focused on the use and
value of the mouse model in TB Drug development despite its lack
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was put forward during the Workshop is that we do not necessarily
have to mimic human disease but try to mimic in animal models the
response of M. tuberculosis to drugs. Certain research groups aim to
achieve in their mouse model similar relapse rates for the HRZ
regimen as those seen in TB patients, or they aim to have a similar
number of bacilli at the start of treatment in mice as is seen in
cavitary lesions in TB patients, or to have a similar means of
exposure to M. tuberculosis as in humans. The mouse model has its
limitations (only one lesion type is present, and most bacilli are
intracellular) and most investigators felt there is a need to inves-
tigate additional animal models with more progressive disease to
address whether these shortcomings in pathology are real issues.
The acute mouse model used by several investigators has severe
limitations in reproducing human pathology and disease, as the
mice have primarily an actively replicating bacillary load, show
a lack of certain pathological characteristics andmetabolic stages of
bacilli. The use of this acute model was discussed to be appropriate
to obtain an in vivo proof of concept (POC), evaluate PK features,
tissue distribution and in vivo activity. Despite its many ﬂaws, most
attendees expressed that the mouse is a reasonable compromise to
qualitatively and rapidly assess the efﬁcacy of new compounds in
a medium throughput manner. In addition, it is at the current time
the only animal model that has been demonstrated to be predictive
of clinical trial data (see also Section 2). A signiﬁcant controversy
still exists among key opinion leaders in the ﬁeld over the most
relevant animal model. It was felt that the state (intra- or extra-
cellular), the number of bacilli and the host’s immune response can
inﬂuence the outcome of treatment studies. The non-human
primate has received much attention in the last years because it
recapitulates human pathology. It is still the mouse, however,
which was considered to be the most practical and appropriate
species to use for early TB drug development.
How relevant is the mouse model? It was generally agreed upon
that the mouse is very useful but that one should not over-
extrapolate mouse model data. The main purpose of the mouse
model is providing information of the efﬁcacy of a novel drug
regimen for tuberculosis over another. This was agreed on by most,
the mouse model being primarily useful in “determining a rank
order of novel drug regimens to increase conﬁdence for a selected drug
regimen to be superior to the standard drug regimen in clinical
studies”. To that effect it will be highly important to conﬁrm that
rank orders of bactericidal and sterilizing potencies obtained in one
mouse model are predictive for humans.164,166 In addition, the
mouse model can provide information on the contribution of
a single drug within the regimen in studies of compounds with
similar background regimens. However whether such results are
predictive of human outcomes is currently not well known as this
clinical data is not always available. It was emphasized that
historically the mouse model has performed well (a few examples
were also described in Section 2). For instance, the mouse model
has shown that RIF and PZA are active against slowly replicating
bacilli, which correlates well with the use of these drugs in the
treatment of human TB. Conversely, INH and SM do not clear these
slowly replicating bacteria in humans and this was predicted in the
mouse.
3.3.2. The various mouse infection models
The two most discussed variables in infection methodologies
were the route of infection with M. tuberculosis and the size of the
inoculum. Some laboratories use the “realistic” low dose aerosol
model; the human infectious inoculum is more closely recapitu-
lated by a low dose aerosol rather than the high dose aerosol
infection model. Although even an inoculum of a so-called “low
dose aerosol” is usually 1 or 2 orders of magnitude higher than theinfectious bacillary dose thought to produce natural infection in
humans. But in a sense, realism is not actually a necessity if one
merely wishes to see if a drug is active or not. Aerosol infection
models are more expensive due to the purchase and maintenance
of a specialized aerosol apparatus. The low dose aerosol model
never achieves a bacterial load greater than 6e6.5 log10 CFU in
immune-competent animals. On the other hand, the high dose
mouse infection model aims to achieve a bacterial burden of 7e8
log10 CFU, thereby aiming to simulate the bacterial burden in
a human cavitary lesion. In humans though there are usually only
one or a few cavitary lesions, while in a mouse with an equivalent
high burden there will be hundreds of individual inﬂammatory
lesions.
It was also discussed that an aerosol with very few bacteria is
possible, but this is constrained by the inherent variation in
delivery. Ideally the ability to deliver just one bacillus into one
mouse lung would be desirable, but the technology just does not
exist. Higher inocula rapidly induce the host immunity, but often
overwhelm the immune system and the mice succumb to disease.
The lymphocytic-predominant granuloma seen in the mouse
intravenous (IV) model bears little resemblance to the necrotic
granuloma seen in the guinea pig aerosol model. Clearly drug
tolerance is observed inmousemodels as around 1% of the bacterial
population is less responsive to drugs and requires long periods of
treatment in order to eradicate. Whether drug tolerance (as seen in
the classical mouse models) or persistence due to the environment
(as seen in animal models with progressive disease) are one and the
same remains to be investigated. Some believe that the emergence
of ‘persistent’ bacilli in cavities is the basis of the long therapy
period required in TB patients. Animal model data shows though
that a small inoculum of M. tuberculosis administered by aerosol to
guinea pigs produces a persistent bacillary subpopulation located
in a speciﬁc microenvironment within primary lesions (in the
necrotic caseous core region and rim of the granuloma).199
Another point of discussion, though rarely discussed, was the
age of the mouse. It should be noted that mice are used in immu-
nology studies when 6e8 weeks of age, and one could argue that at
this age mice are still not fully immunocompetent. A related point
of discussion concerned body weight and blood volume. Some
investigators used 4 week-old mice to administer intravenous
infections in volumes of 0.5 ml, which is large for mice of this
young age.
3.3.3. Readouts for drug efﬁcacy
Several issues regarding the endpoints and the mouse models
themselves were discussed. Regarding accurate endpoints in
treatment trials, the method used for enumerating bacteria from
organ homogenates should be carefully (re)considered given the
possibility that some non-culturable bacteria in samples of animal
tissues may not form colonies on solid agar. Liquid media, such as
BACTEC or MGIT, was suggested as a method to enhance sensitivity
for ﬁnding low numbers of CFU and to gain some insight into the
state of the bacillus at the time point examined. Liquid testing using
the MGIT system is also now the method of choice for sputum
evaluation to assess culture conversion for clinical trials. Several
automated liquid culture systems have shown greater sensitivity
than the traditional solid-media cultures the acknowledged
increased in the mycobacterial recovery rate of liquid media, which
is likely due to a more mycobacterial populations being able to
recover in liquid culture than on solid media. This is supported by
in vivo and in vitro observations that subpopulations of
M. tuberculosiswith different states of metabolic activity co-exist in
old liquid cultures,200 as well as in liquid cultures with bacterial
growth from chronic infected mice that do not grow on solid
media.201
Text box 5.
Lessons learned from the workshop: on in vivo efficacy
models
 The mouse model is still the animal model of choice as
it represents the only animal model that has been vali-
dated to date by testing regimens and treatment dura-
tions known to work in patients
 Regarding the route and inoculum of TB infection in
mice, realism is not actually a necessity if one merely
wishes to see if a drug is active or not
 The main role of the mouse model is to establish a rank
order among novel drug regimens in order to increase
the confidence for a selected drug regimen to be
superior to the standard drug regimen in clinical studies
 Relapse studies are critical as the bactericidal activity in
mouse model is not always predictive of sterilizing
activity
 Liquid media may be a more sensitive growth indicator
 Diversity of animal models is desirable, standardization
of protocols and TB strains within a laboratory is
a requirement
 Publishing all methodological details is encouraged
 Confirmation of results of in vivo activity in another
infection model and against another TB strain from
a characterized strain collection is strongly
recommended
 Include all controls (including the two drug combina-
tion when there is a substitution of one agent in a triple
drug regimen)
 Always test and report MIC data on the M. tuberculosis
strain used in the in vivo studies
 Confirm findings in a second animal model to address
evaluation of efficacy against persisting bacilli in
advanced lesions. [Currently of theoretical concern
only: good comparative studies between mouse and
other models are missing]
S.G. Franzblau et al. / Tuberculosis 92 (2012) 453e488 473Another topic of discussion in at least two laboratories was the
issue of drug carry-over at the time of enumeration of bacterial
colonies in the organs. CLF and TMC-207 both have long half-lives,
high tissue distribution and tissue binding, and therefore drug
might still be present at the time of sacriﬁcing the animals. The ﬁrst
indication that drug carry-over is an issue is observed when dilu-
tions of organ homogenates do not have the expected reduction in
bacterial number. Another indication might also be the lack of
correlation between the bacterial number and the gross pathology
observation. Several methods have been described to reduce the
carry-over of drug in agar plates, including using LJ medium or
7H11 with 5% bovine serum albumin (BSA) for TMC-207,202 and
using 0.4% activated charcoal for CLF.203 Relapse studies will then
show the true sterilizing potential of these drugs and drug
combinations.
The guinea pig model shows primarily extracellular bacteria in
the central caseum and in a rim of ﬁbrosis or non-mineralized
necrosis. Some bacteria occur singly, but most are in small clus-
ters. Methods for obtaining bacterial load data from particular
guinea pig tissues that allow cultivation of single organismsmay be
needed in order to assess the true effect of chemotherapy. It was
pointed out that colony forming units (CFU) measures by plating
organ homogenates on solid agar are often inaccurate since they do
not necessarily include just single bacilli but rather small clumps or
conglomerations. There was discussion around the hypothesis that
these clusters represent a type of bioﬁlm. Hatfull et al. found these
M. tuberculosis bioﬁlms in vitro to consist of bacteria surrounded by
a layer of free mycolic acids.66 Although the bioﬁlm hypothesis was
not accepted by everyone, it was agreed that the extracellular
bacteria in these micro-environments are unique and should be
targeted by drug treatment. Another topic of discussion was about
the drug refractory nature of these persisting bacilli being a drug
penetration issue, by drugs not getting through this ﬁbrous rim and
extracellular lipid matrix. The ability to determine the penetration
of TB drugs into a granuloma was seen as an important gap in the
current knowledge about TB drugs.
3.3.4. Long term treatment studies and relapse
The main goal of long term models is to assess the activities of
new regimens in terms of shortening the length of treatment
versus the standard regimen. This might be best modeled in the
high dose aerosol model because it resembles a similar treatment
length as those used in the clinic (the intensive and continuation
phase), whereas in the low dose aerosol infection model shorter
treatment times would have to be investigated and correlated to
the clinical conditions. Relapse studies were discussed as being
a critical component of drug evaluations to assess the sterilizing
potential of new drugs and regimens, however, some laboratories
are reluctant to consider long term relapsemodels due to the lack of
clinical data that proves relapse data in mice are required. A poster
presented at the GRC meeting (which is now published166),
however, showed that bactericidal activity is not always predictive
of long term sterilizing properties and thereby highlights the
importance of relapse studies. Our head-to-head studies showed
a similar result for the moxiﬂoxacin containing regimens (see also
Section 3.5.3).
It was discussed that relapse studies usingmice in fact cannot be
realistic as in the clinic relapse rates of 5%with standard therapy are
observed. If in animal experiments relapse rates reachedmerely 5%,
the experiment will not achieve sufﬁcient statistical power to ﬁnd
any statistical beneﬁcial effect of a new drug regimen over the
standard regimen. Investigators commented on this by explaining
the methods used in their laboratories to obtain higher relapse
rates; this was achieved by either infecting animals via the IV route
which gives higher relapse rates than infection by inhalation, or byincluding different lengths of drug treatment. Using one of both
strategies will ensure a sufﬁciently powered experiment which can
then be used to rank order drug regimens versus the standard drug
regimen. An example was discussed, where data from relapse
studies was used to showan intermittent treatment regimenwas as
effective as daily dosing (such as the Denver regimen).204
3.3.5. The bacterial strain
The overwhelming variety of M. tuberculosis strains used by
different laboratories was the ﬁrst striking realizationwhen visiting
the different laboratories involved in TB drug evaluations in animal
models. In addition, a difference in virulence of these strains was
also reported which could be caused by each investigator propa-
gating their strain using in-house protocols instead of using a single
reference method. Issues regarding cultivation methods have been
the topic of papers for close to a century, mouse passage and
pellicle growth are usually the methods used to generate virulent
stocks.107
Relying on one bacterial strain for efﬁcacy studies was felt to be
a less desirable practice due to possible unique properties of
a particular strain; rather, several diverse strains including
a current clinical strain should be included in animal studies. To
have well characterized M. tuberculosis strains analyzed by whole
genome sequencing and metabolomics, proteomics and drug
susceptibility testing was considered to be a necessity. The
consensus was to validate and standardize the bacterial strains
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models, since there is great advantage to be gained from conﬁrming
data of certain drugs and drug regimens in different models. Plus
there needs to bemore discussion onwhat criteria a bacterial strain
needs to have to be deﬁned as “well characterized”. Of importance,
the in vitro drug susceptibility of the strains should be reported for
the reference drugs, to ascertain that results from one laboratory to
another can be compared.
3.3.6. Statistical analysis
Statistical methods are of key importance and different methods
are used depending on the question asked. Methods used were
found to be very similar across laboratories, and often assistance of
a statistician was provided to answer new questions. Power anal-
ysis prior to the experiments is required to determine the number
of animals used in the experiment. The primary data analysis for
mouse models is usually a one-way analysis of variance (ANOVA) of
the log10 CFU bacterial loads, with t-distribution based contrasts
comparing individual treatments. A Dunnett’s test is an appropriate
method for comparing all new compounds to untreated controls,
while controlling the overall error rate in that set of comparisons at
the usual 0.05 level. Also Bonferroni and Tukey statistical tests are
appropriate tests for a pairwise comparison between treatment
groups. Evidence of differential relapse based on detection (yes/no)
of TB bacteria would be established using a Fisher’s exact test
comparing rates of relapse between two experimental groups. In
experiments with n ¼ 5e10 per group, power to identify signiﬁ-
cantly different relapse rates is very low. Therefore in order to
increase the statistical power, more treatment groups are imple-
mented with various lengths of treatment, or a higher relapse rate
is aimed for in order to see signiﬁcant differences between different
treatment regimens. Relapse information obtained from mouse
models should always be interpreted with great care and seen as
trends in relapse differences between treatments.
3.3.7. Screening sequence
Recommendations were made regarding the evaluation of
single drugs for which short term models can be utilized, and for
the evaluation of the sterilizing activity of single drugs to use
a minimum of a 4-week treatment regimen. To assess drug
combinations against tuberculosis, a 3e6 month long study using
a chronic infection mouse model was recommended, and for
relapse studies a 3-month drug-free interval should be included.
Internal controls should always be included, such as an HRZ
combination arm for drug regimens and an INH arm for single drug
studies. It was discussed during the workshop that studies should
be repeated in a different laboratory to conﬁrm the results and to
rule out effects of speciﬁc differences in methodology on outcomes
before an agent is taken into the clinic. In light of our later ﬁndings,
we can reﬁne that statement. To conﬁrm in vivo results we now
strongly recommend that the repeat experiment is performed with
a different TB strain, in another infectionmodel (changing the route
of infection, time of treatment) which is preferably conﬁrmed in
a second laboratory (see also Section 2.7: Recommendations).
The choice of a drug dose in vivo was discussed with two
different research groups, and it was mentioned that for initial
in vivo evaluations a high drug dose is appropriate to give the
compound the best chance of success. For many studies in the
mouse model, a dose is chosen based on having a similar AUC in
human patients if this information is available. For preclinical work
with unknown lead compounds, the PK characteristics and toxi-
cology will initially determine the drug dose. Subsequently, dose
fractionation studies with TB drug candidates are essential to assess
the predictive parameters that determine in vivo activity (such as
AUC/MIC, or Time over MIC). In addition, the hollow ﬁber methodmight give additional information at a later stage of TB drug
development regarding dose selection and optimal dosing regimen
of single drugs.205 Although dose selection is a critical component
of TB drug development, during our visits not many groups had
lead compounds in that stage of TB drug development. The CPTR
(Critical Path for a New TB Regimen) effort will however release
a white paper focusing on the gaps and issues in advancing drug
regimens to the clinic and this will address speciﬁcs on the hollow
ﬁber model, dose selection and more.
In several recent reviews and during visits of the various labo-
ratories in TB drug development, different strategies in TB Drug
R&D became apparent.6,81 Novartis spoke about following a strict
“Critical Path” with an emphasis of MIC, ADME and PK followed
only then by testing in vivo efﬁcacy in mice. At J&J the emphasis was
clearly to increase the selectivity index of their initial hits [the ratio
of cell cytoxicity over inhibitory concentration against
M. tuberculosis (CC50/IC50)] of the diarylquinoline compound
series until no improvement of the in vitro activity could be
reached. This was followed by extensive ADME and PK proﬁling of
a few compounds (resulting in ‘compound polygraphs’), and in vivo
testing in the mouse model. Data of the selected compounds were
then summarized in a ‘compound monograph’. The J&J strategy by
Koen Andries was rapidly known as the “3M” approach focusing on
“MIC, mice and man”. Although the MBC and NRP activity were
considered by K. Andries as useful additive in vitro data, these
would only come as secondary screens. At GlaxoSmithKline the
emphasis lies heavily on PK/PD in vivo analysis and only good leads
will be considered to go forward for in vivo efﬁcacy testing. Most
laboratories use some variety of a short term mouse model initially
(starting treatment a few days after infection, or against actively
replicating bacteria), followed by an established infection model to
look at the sterilizing activity of the compound.
3.3.8. Scientiﬁc questions
An interesting question was raised whether an immunocom-
promised mouse such as the GKO mouse model could completely
eradicate the disease upon drug treatment, or whether an intact
immune response is required for a durable cure. The idea behind
the published GM-CSF mouse model to initially rapidly kill more
than 90% of the bacilli so that only drug tolerant bacilli remain, and
then to evaluate the activity of single compounds against the drug
tolerant bacilli.206 The use of immunocompromised mice for this
purpose will shorten the treatment periods signiﬁcantly and
therefore the model could be used early in TB drug development to
see if a compound has any sterilizing activity against slowly repli-
cating or drug tolerant bacteria.
There are multiple issues regarding assessment of new
compounds, and not all of these are currently adequately
addressed. Pharmacokinetic and pharmacodynamic issues are
paramount, such as determining the extent of drug penetration into
TB lesions [not many results yet], understanding how the local
environment [pH, hypoxia, etc.] inﬂuences activity, and identifying
which drug of a drug regimen participates at what time during
treatment? There are also many issues surrounding the study of
drug combinations that need to be addressed (proper PK, antago-
nism, toxicity issues, formulations, timing of drug delivery etc.).
Another question that came up several times during visits was
the usefulness of the MBC value of a new compound in regards to
its in vivo killing kinetics. Most investigators see the MBC as addi-
tional but not critical data. Whether the MBC is reached at the site
of infection in vivo will largely depend on the PK features of the
molecule. For instance, RIF has a higherMBC (2e4 mg/ml) compared
to its MIC (0.03 mg/ml) and therefore the ratio of the MBC/MIC is
relatively high. In vivo however these drug levels are in fact
reached due to the favorable PK and protein binding features of
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a good predictor for sterilizing activity in vivo. Since a good
sterilizing agent should display good activity against actively
replicating and other subpopulations, it is better to have
a compound with a low MIC and reasonably good activity against
NRP, as well as displaying good tissue distribution. It is important
to combine and interpret all data on a compound in context to
each other.
Another topic of discussionwas the problemwith dogmas in the
tuberculosis ﬁeld, and one of these is about the location of bacilli in
a TB infection. A lot of speculation is ongoing about the possible low
pH in the necrotic lesions, and most of the bacteria being extra-
cellular while there is little proof for this. All recognize that these
would be important studies to conduct. In addition, most investi-
gators realize thatmost animalmodels do not reﬂect these features.
3.3.9. Standardization of infection models?
The issue of the need to standardize assay conditions is a difﬁ-
cult one and in the end the diversity was seen as being positive.
There are many issues regarding assay standardization and there
will likely be no harmonization amongst laboratories performing
studies in a certain manner. It is in fact likely that this diversity will
allow discovery of a greater number of compounds. It was
acknowledged that there is deﬁnitely added value in having
investigators use only standardized and reproducible protocols
within their laboratories,and that the infection model be highly
reproducible and be able to recapitulate the already available
clinical data. Investigators should calculate statistical power prior
to a study in order to have high enough numbers of animals to
make meaningful conclusions, and they should thoroughly record
all variables relevant to the assessment of the animal. Regarding
methods, it was recommended to report every detail in publica-
tions such that all possible variables could be reproducible. There
will be a continuous effort to ﬁnd alternatives to animal models
such as computermodeling, the hollow ﬁber or artiﬁcial granuloma
models, but thesewould have to be critically assessed and validated
thoroughly with existing drugs and compared to the mouse which
has been fairly predictive for many years. There are many gaps and
questions in TB drug development where these models might
actually provide an answer (establishing an appropriate drug
dosing regimen, selection of drugs based on penetration in the
granuloma, etc.), but all of these new methods will need more
validation. Important is the continuing need to analyze the current
state of affairs and understand the limitations and strengths of each
method.
3.4. Overview of the methods and key deﬁnitions
There are two main mouse models of infection for TB drug
development which are primarily addressed in this strategic plan.
Both methods differ in the route of infection, and these were the
intravenous and the aerosol infection model. The two methods
were the most reported ones by the participants at the time of the
survey. We realize that more recently several groups are also
utilizing the intratracheal and intranasal infection approaches.
Investigators have reported reproducible results to us for the
intranasal infection when the inoculum is higher than 200 CFU.
Unfortunately, we were constrained under this effort to focus on
the most widely used approaches which are the intravenous and
aerosol models.
Both of the studied infection models differ signiﬁcantly in their
approach, on the site of infection and the activation of the immune
response. After intravenous infection, assuming the bacterial
inoculum is correctly prepared as a single cell suspension, there is
a characteristic pattern of 90% of the bacilli being deposited in theliver, 10% in spleen and only 1e2% will initially reach the lung. In
terms of the spleen, the bacilli are directly delivered into
a lymphoid organ, resulting in rapid induction of both innate and
later acquired immunity in this organ. For the aerosol infection all
bacteria are delivered in the lung and only after the initial days will
there be dissemination via the bloodstream to other organs. The
usual inoculum used in mice is w100e5000 bacilli by aerosol
infection, but a range of inoculums have been reported. The
immune response is initially activated in the lung.
3.5. Head to head comparisons of the in vivo methodology
Methodologies for preclinical animal models testing of drugs
againstM. tuberculosis vary from laboratory to laboratory; however
it is unknown whether this heterogeneity in experimental param-
eters results in different outcomes regarding new TB agents used
alone or in combination. The objectives in identifying the most
important variables in the mouse infection models are two-fold.
The ﬁrst goal is to identify the most important variables that can
inﬂuence results in animal models, thereby informing new inves-
tigators. The second goal is to improve the TB drug development
process by implementing the most effective and accurate methods
for drug evaluations to eventually identify highly effective drugs
with demonstrated sterilizing activity.
In order to determine whether the results obtained in the most
commonly used mouse models are comparable to one another,
a series of head-to-head comparisons of drug regimens in three of
the most commonly used mouse models was studied under this
project [the intravenous injection, a low dose and a high dose
aerosol infection model of M. tuberculosis] in two commonly used
strains of mice. The main goal was to determine if outcomes in
mouse efﬁcacy models can vary based on the methodology used. A
number of variables were identiﬁed from the start of the project,
others were included during the duration of the project, and the
following variables were selected for the head-to-head evaluations:
the inﬂuence of the mouse strain on drug efﬁcacy, the route of
infection (aerosol, intravenous infections evaluated on drug efﬁcacy
and relapse), inoculum conditions (fresh versus frozen cultures,
water versus broth as diluent, the size of inoculum used for infec-
tion), the preparation and formulation of drugs, the timing of drugs
when administered in combinations and the M. tuberculosis strain
used for infection of the mice.
3.5.1. Inoculum of M. tuberculosis
In a few initial mouse experiments, a couple of variables
regarding the M. tuberculosis inoculum used for infecting the
animals were studied. A fresh bacterial culture versus a frozen
aliquot of M. tuberculosis was compared for infecting the mice. The
results showed that both inoculums gave the same in vivo bacterial
growth kinetics in lungs and spleens. There was also no difference
seen in the in vivo bacterial growth depending on the diluents used
to prepare for the inoculum. The same results were achieved with
bacteria either in H2O or 7H9 media, or when a fresh bacterial
culture was frozen and thawed, and diluted with H2O. When
incubating the organ dilutions on 7H11 plates for enumeration of
bacteria in organ homogenates, incubation in presence or absence
of CO2 had no effect on the bacterial number (CFU). The only
difference was the faster growth of the bacteria in presence of CO2
(colonies were readable in 2.5 weeks instead of 3.5 weeks without
CO2 incubation).
3.5.2. Choice of mouse strain
A head-to-head experiment was aimed at evaluating drug efﬁ-
cacy of the standard drug regimen INH, RIF and PZA in two of the
most commonly used mouse strains. The mouse strains were
Text box 6.
Key definitions on in vivo efficacy models
 Acute infection: defines an M. tuberculosis infection in
animals with actively replicating bacteria. In standard
laboratory mice, this is an infection established in less
than two weeks (which is before the adaptive immune
response is activated).
 Chronic infection: defines an M. tuberculosis infection
in animals where the bacterial load progresses to
a steady-state in CFU due to the adaptive immune
response (and is considered the opposite of an acute
infection). The bacilli are considered to be (non- or)
slowly replicating.
 Low dose infection: This infection model will progress
slowly into a chronic infection in standard laboratory
mice, and the animals are able to control the infection.
Typically this is obtained after delivery by aerosol of 50
e100 CFU of M. tuberculosis.
 High dose infection: This infection model will progress
rapidly and develop a high bacterial burden, and the
animals will succumb to disease 2e4 weeks after
infection. Typically this is obtained after delivery of
a high inoculum by the intravenous route, or after 3.5
log10 CFU by the aerosol route.
 Drug exposure: Defined as the overall drug levels that
the animal is subjected to treat an infection which is
typically based on the serum or plasma levels of the
drug.
 Initial/intensive phase of treatment: the initiation of
therapy which consists typically of 3e4 drugs associ-
ated with a large fall in bacterial numbers. This phase
typically lasts for 2 months.
 Continuation phase of treatment: the prolonged phase
of therapy usually with two drugs only, aiming to
eradicate a small persisting bacterial population. This
phase typically lasts for 4 months.
 Latent infection: defines a clinical condition inwhich the
person is PPD skin test positive and is thought to have
been infected with TB. The TB patient has been able to
control the infection, and does not show any signs or
symptoms of active disease.
 Persisters: defined as bacteria that can survive long
term exposure to drugs to which they are fully
susceptible on the basis of MIC testing, and which
represents itself as phenotypic tolerance. Persisters can
occur in response to drugs, the immune response and
hostile micro-environments (such as hypoxia, nutrient
depletion, etc.).
 Dormancy: a term often used in the past, which might
not be appropriate for M. tuberculosis as metabolic
processes have been shown to continue in persistent
organisms in vitro, although to a lesser extent.
 Cure or sterilizing activity: is synonymous with
observing no relapse of infection inmousemodels after
termination of treatment. Relapse in mice should be
tested at least 3 months after therapy is completed.
[These terms are preferred over the misused term
‘durable cure’. ‘Sterilizing activity’ is preferred over
‘sterilization’ as sterilization cannot be confirmed
experimentally, whereas sterilizing activity is
a measurable activity against persisting bacteria that
can result in cure].
 Bactericidal activity: This term refers to the activity of
a compound or drug regimen as assessed during or
immediately after termination of drug treatment. [This
term is preferred over the often misused term ‘steril-
izing activity’ to describe the activity of a compound
during treatment].
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aerosol with M. tuberculosis and the three-drug combination was
administered for 4 months using either Balb/c or C57BL/6. The
results showed that the bactericidal efﬁcacy of the standard drug
regimen was not signiﬁcantly different in the two mouse strains
infected by aerosol.164 These results show that for the bactericidal
activity of the tested drug regimen no difference was observed.
The question whether relapse rates after drug treatment would
be similar in various mouse strains was not investigated, and this
should still be addressed in future as the role of the immune
response will be more prominent at this stage. It has been well
established that mouse strains have varying resistance towards
a M. tuberculosis infection,207 and therefore relapse of infection
might be delayed in a more resistant mouse strain. However, the
more important question is to what extent the ranking of drug
efﬁcacies for different drug regimens in relapse studies might
change for the various mouse strains, if at all, and this remains to be
evaluated. A study comparing relapse results of different regimens
using inbred mice versus Swiss mice [the mouse strain used in
many historical experiments validating the IV mousemodel] would
answer these questions.
3.5.3. Route of M. tuberculosis infection
In a next series of head-to-head mouse model studies,
a comparison was performed between three mouse models based
on the route of M. tuberculosis infection and inoculum size. The
mouse infection models included the HDA, LDA and IV models
(Figure 9). Three treatment regimens were evaluated for in vivo
efﬁcacy during the initial treatment stage and during relapse of
infection. The standard drug regimen (INH, RIF and PZA), and the 2-
drug combination (RIF and PZA) were evaluated, as well as the
combination regimen where moxiﬂoxacin (MXF) was included as
a replacement for INH in the standard regimen (MXF, RIF and PZA).
Drugs were administered for a duration of 4e6months, and relapse
was assessed 3 months after termination of treatment. The reason
for inclusion MXF was that the ﬂuoroquinolone is currently in
phase III clinical trials for TB treatment.208 This study also tried to
address the observation seen by others using mouse models of the
antagonism between the three standard drugs and thereby seeing
a beneﬁcial effect of replacing INH with moxiﬂoxacin, which has
been a controversial ﬁnding in the ﬁeld.152
The results of the studies were published and therefore are just
summarized here.164 When comparing the efﬁcacy of the drug
regimens tested in the LDA mouse model versus the IV model, it
was clear that there was a delay in bactericidal activity in mice
infected by the IV route versus LDA by the standard drug regimen.
The efﬁcacy results during drug treatment showed statistically
similar activity for both three-drug combinations (MRZ and HRZ)
for all time points tested, and this in all three mouse infection
models. Therefore, the ranking of the tested drug regimens was
found to be similar during treatment for all three infection models.
Relapse results showed statistically similar relapse rates for the
following drug regimens and lengths of treatment: 2HRZ/
4HR ¼ 2MRZ/2 MR for both the HDA and IV infection models, and
2HRZ/2HR ¼ 2MRZ/1 MR for the LDA. Of importance, 2MRZ/2 MR
showed improved sterilizing activity by showing signiﬁcantly less
relapse when compared to 2HRZ/3HR (only statistically signiﬁcant
for the IV infection model). For the HDA group, a similar trend was
observed but this was not statistically signiﬁcant due to a low
number of mice relapsing infection. In the LDA model virtually no
relapse was observed after 2MRZ/1MR treatment, while there was
10% relapse seen after 2HRZ/2HR treatment. These results showed
that the bactericidal activity does not necessarily reﬂect the
relapse results of a drug regimen (as is discussed in De Groote
et al.164).
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Figure 9. Bacterial numbers in lungs of Balb/c mice after HDA (top), IV (middle), or
LDA (bottom) infection with M. tuberculosis and 1, 2, 3, 4, 5 or 6 months of drug
treatment. Drug treatment included either two months INH, PZA and RIF, followed by
INH and RIF (-); or two months MXF, PZA and RIF, followed by MXF and RIF (:); or 6
months of PZA and RIF (B). Taken from reference 164.
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mouse infection models, the IV groups showed signiﬁcantly more
relapse than for the groups from both aerosol models. This obser-
vation has been made by others as well. It is possible that the
difference in immune response at the initial site of infection is
responsible for this. After an IV infection, a high number of bacilli is
introduced in liver and spleen (only 1% is found early in the lung)
which may have an effect on the immune response thereby inﬂu-
encing the frequency of relapse. A delayed bactericidal activity in
the IV model might also contribute to a faster relapse of infection.
The increase in relapse rate was not caused by a higher number of
resistant colonies in the IV infected groups.In conclusion, the results comparing the in vivo efﬁcacy of drug
regimens in three mouse infection models gave the same end
conclusion and therefore showed us that the route of infection was
not a variable that changed the outcome of the in vivo efﬁcacy
study. These studies showed similar results in bactericidal efﬁcacy
for the MXF-containing regimen versus the standard drug regimen,
regardless of the mouse infection model used (either low or high
dose aerosol, or the IV infection model). In contrast to observing
similar bactericidal activity of MRZ and HRZ over the initial months
of treatment, the relapse rates for the MXF-containing regimen
were signiﬁcantly lower than these for the standard drug regimen
in the IV infection model. These results conﬁrm the importance of
evaluating both the bactericidal and sterilizing efﬁcacy of drug
regimens in mouse models in order to select the drug regimen that
can lead to cure. In this case the IV infection model was the only
model showing statistical signiﬁcant superiority of the sterilizing
activity of the MXF-regimen over the standard regimen, which was
not observed for both aerosol infectionmodels due to lower relapse
rates.
Clinical trials have been conducted to assess the beneﬁt of MXF
in standard TB drug regimens. Tuberculosis Trials Consortium
Study 28 was conducted based on the mouse model data of
substituting MXF for one of the TB drugs in the standard regimen
(HRZ).154,209 A trend in improvement with MXF (99/164 were
culture negative vs. 90/164 for INH) was seen at 8 weeks, but it did
not reach statistical signiﬁcance (p ¼ 0.37) when substituting INH
in the standard regimen for MXF. The results of our mouse studies
support the ﬁndings of human TBTC study 28, where no signiﬁcant
difference was seen in bactericidal activity when MXF was
substituted for INH in a daily regimen for 8 weeks. The mouse
studies discussed here predict that MXF might only show signiﬁ-
cant beneﬁt in later stages of the clinical trial. However, there are
also other reported IV infection studies using Swiss mice which do
not show improved relapse rates of the MXF-containing regimen
over the standard regimen.210 In that report, the relapse results
obtained with the MXF-containing regimens in the high dose
aerosol infection model209,211 could not be conﬁrmed in the IV
infection mouse model.166,210 Ultimately, the long term follow-up
data of the ReMoxTB clinical trial will be highly informative
regarding the predictive value of the mouse infection models and
relapse studies, and is currently underway (described at www.
tballiance.org).
Since the focus of this project was to concentrate on drug
combination studies, it is certainly possible, and perhaps likely, that
treatment with single drugs would show a difference in drug effect
between the different animal models. It would not be surprising
that the actively replicating bacterial population in the IV and HDA
infection models behave differently for compounds with a certain
mode of action, when compared to bacteria in a chronic state after
an LDA infection. Additional experiments with a panel of TB drugs
targeting certain bacterial populations would be required in order
to address this question.
3.5.4. Drug preparation, formulation and dosing schedule
The experiment aimed at determining the effect of formulation
and dosing schedules of drugs in combination treatment regimens
on the efﬁcacy in mouse infection models. Balb/c mice were
infected by HDA and drug treated with the standard regimen of
INH, RIF and PZA, with and without MXF, and compared to theMXF,
RIF and PZA combination. Two different RIF formulations with
alternate schedules of drug deliverywere compared in this study. In
the ﬁrst method RIF was dissolved in water and dosed at least 1 h
prior to other drugs, and in a second method RIF was administered
in 5% DMSO 1 h after combinations of INH or MXF and PZA. The
results of the studies were published and therefore are just
Figure 10. Phylogenetic tree of H37Rv and H37Ra, adopted and redrawn from
reference 165. H37 was isolated from a human patient in 1905 and propagated until at
the Trudeau Laboratories. When the avirulent H37Ra was separated, the two H37Rv
and H37Ra were separately maintained and the parent was no longer available.
Within the H37Rv from various laboratories there has been divergence based on single
nucleotide polymorphisms (SNPs).165
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difference seen in drug efﬁcacy of the tested drug regimen
depending on the RIF formulation or the dosing schedules used
here. Analysis of drug concentrations was performed on plasma
samples of mice to assess the pharmacokinetics of INH, RIF and PZA
after a single drug administration of RIF (using the same RIF
formulation methods as described above in the efﬁcacy study).
There were some slight differences seen in the kinetics of the
concentrationetime curves of RIF depending on whether the drug
was ground in a mortar in water or prepared as a DMSO solution,
but overall drug exposures of RIF were not signiﬁcantly different.
Overall, no signiﬁcant differences were seen in the AUC of the drugs
depending on the RIF formulation or the dosing schedules used.
The results here show that at least for the drug combination tested,
the formulation was not the critical variable that changed the
efﬁcacy results in a signiﬁcant manner. Grinding RIF in water
showed at least as good, and possibly even better in vivo activity
than when formulated in DMSO. Therefore, we recommend using
water and careful grinding of RIF to smaller particle size as the
optimal formulation for RIF.
3.5.5. Strain of M. tuberculosis
After testing many variables, it became clear that the main
variable that was not yet addressed was (the source and propaga-
tion of) theM. tuberculosis strain used for in vivo infections, and that
this sole variable might in fact explain some of the discrepancies
between experiments performed under this project and by others.
In the head-to-head studies described in this section, the combi-
nation of HRZ was in all three infection mouse models signiﬁcantly
more effective than the RZ dual therapy. In none of the three
infection models was an antagonism of H in the HRZ combination
observed. Antagonism between the three standard drugs has been
shown by others,212 where it was demonstrated that the 2-drug
regimen of RZ after removal of INH performed better than the
standard 3-drug regimen HRZ. In order to prove that the bacterial
strain might be the most important variable to explain the
discrepancy between laboratories (in this case the antagonism
between HRZ), an experiment was initiated where all other vari-
ables (such as inoculum, route of infection, mouse strain, drug
formulation, dosing schedule, and others) were kept identical
except for theM. tuberculosis strain used for infecting the mice. The
drug regimens HRZ, RZ, MRZ and HMRZ were evaluated in Balb/c
mice infected by HDA with either M. tuberculosis H37Rv (Origin:
Frank Collins, mouse passaged176,209) or M. tuberculosis Erdman
strains (Origin: Trudeau, pellicle grown164). The results of the
studies were recently published213 and are therefore just summa-
rized here. The results showed that there was a signiﬁcant antag-
onism observed in HRZ in themice infected with theM. tuberculosis
H37Rv used, while this was not seen in mice infected with
M. tuberculosis Erdman. At the time of this ﬁnding, the result could
not just be explained by the strain difference of using either H37Rv
versus Erdman as other investigators using M. tuberculosis H37Rv
for infecting mice have never reported seeing antagonism in the
standard drug regimen [such as using the Swiss IV mouse model
with M. tuberculosis H37Rv of uncertain derivation (obtained from
Laboratoire de Bacteriologie, Faculte de Medecine Pitie-Salpetriere,
Paris, France)166,214,215].
Therefore, a ﬁnal head-to-head study was performed to conﬁrm
that the antagonism is a strain speciﬁc phenomenon, and included
clinical strains. Ultimately, the most important question is to know
which drug regimens will performwell or better than the standard
drug regimen against clinical TB strains. In a recent trial,
a comparative study was conducted which evaluated 5 bacterial
strains: 2 M. tuberculosis H37Rv [of two different origins164,176,209],
M. tuberculosis Erdman, HN878 and CDC1551. The recentlypublished data213 indicates that 4 out of 5 M. tuberculosis strains
never showed any antagonism in HRZ (with HRZ being signiﬁcantly
better than RZ), whereas one of the H37Rv strains (Origin: Frank
Collins, mouse passaged216) showed an entirely different drug
proﬁle with RZ being as effective as HRZ.
The most surprising result was that both H37Rv strains gave
a different result in this study. Although many laboratories use
H37Rv, there are many variations of this lab-adapted strain in
circulation. H37Rv was initially derived from a clinical isolate,
named H37, which was obtained in 1905 from a patient E.R. Bald-
win with pulmonary tuberculosis (Figure 10). The H37Rv (ATCC
25618) strain is maintained at the Trudeau Institute in New York,
although unfortunately, the original H37 clinical isolate has been
lost. Strain ATCC 27294 (Trudeau Mycobacterial Collection;
TMC102) is also frequently used as a representative of H37Rv in
studies, and treated equivalently in the literature. ATCC 25618 and
ATCC 27294 were both isolated from the same patient in different
years, and both are fully drug susceptible. The TMC102 strain was
derived from the 1905 human-lung isolate H37 in 1934 by W.
Steenken, and deposited by GP Kubica. ATCC 25618 was identically
derived, but deposited by AG Karlson. Despite these differences
within H37Rv both maintain virulence.165,217 Besides these different
sublineages of H37RV, the propagation of the bacterial strain in
a laboratory can also lead to genetic alterations. A recent paper
details the elaborate study of a group of investigators to assess the
consistency of the genome sequences among H37Rv strains in use
by six different laboratories and the extent to which the strains
have diverged from the original sequenced H37Rv strain by whole-
genome sequencing.165 It was clear from the results of the six strain
varieties that besides different polymorphisms, nucleotide substi-
tutions, insertion/deletions, and multiple IS6110 transposition
events were observed (Table 9 and Figure 10). Two of the ATCC
25618 strains demonstrated frameshift mutations þ GC in the mas
gene (encoding mycocerosic acid synthase). The authors here
concluded that the genome-wide catalog of genetic differences can
help explain any phenotypic differences that might be found,
including the observed frameshift mutation in themycocerosic acid
synthase gene which caused these two of the tested strains to be
deﬁcient in biosynthesis of the surface glycolipid phthiocerol
dimycocerosate (PDIM), however, both are known to retain
virulence.
The results described here show the importance of the
M. tuberculosis strain in mouse efﬁcacy studies, and therefore we
highly recommend for investigators to use only highly character-
ized strains with known background and conﬁrm any drug regimen
results in mouse infection models against a second M. tuberculosis
strain, preferably a currently relevant, characterized clinical isolate.
Table 9
Descriptions of the two differentM. tuberculosisH37Rv strains deposited in the ATCC.
(See description in Ref. 165.)
ATCC 27294 ATCC 25618
Origin Steenken, 1934 Steenken, 1934
Depositor Kubica Karlson
IS6110 777777475760771 777777477760771
777777477760771
PDIM No mutations in mas gene Frameshift in mas gene
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Under this effort, certain parameters regarding mouse infection
models for tuberculosis were re-evaluated in head-to-head exper-
iments in the laboratory. However, during the course of these
in vivo experiments as well as through discussion at the laboratory
visits and during the workshop, additional questions or remaining
topics of discussion have arisen on animal models for TB drug
testing. Some of these are listed below together with the lessons
learned.
3.6.1. Is standardization needed?
In preclinical testing of experimental compounds against
tuberculosis, there are various mouse models used by different
investigators in the ﬁeld as described above. By surveying investi-
gators, visiting laboratories and performing in-house experiments
it has become clear that the standardization of the methods within
a laboratory is deﬁnitely recommended. Certain crucial parameters
of mouse infection models have been identiﬁed through our efforts
that can change the outcome of drug efﬁcacy trials in TB drug
development. These results have shown that within the same
laboratory it is important to standardize the mouse infection
models used so that results can be compared from experiment to
experiment. Standardization in terms of using a certain inoculum of
bacteria, start of infection, appropriate qualitative controls to track
the infectivity and growth characteristics of the strain in every
experiment, inclusion of drug controls, etc. In addition, every
laboratory should work with a well characterized M. tuberculosis
strain with known origin and have an SOP for culturing and prop-
agating their bacterial strain. A log is highly recommended for the
TB strain used in vivo to track the virulence performance after
repeated culturing, the passage number should be noted (and
should be limited to 3e6 passages), and results of positive controls
tracked.
As for standardization of mouse models across laboratories,
several discussions were held on this topic. The consensus was that
there was far more to be learned from multiple mouse infection
models used across different laboratories instead of relying on one
single infection model used by every laboratory. Conﬁrmation of
a superior activity of one drug combination in multiple animal
models in different laboratories was only seen as increasing the
conﬁdence to move with that drug regimen further into clinical
trials.
3.6.2. The in vivo testing sequence
Among mouse infection models, there are clear differences in
bacterial responses seen to drugs depending on the stage of
infection, the effect of the immune response, the size of infection
inoculum used and on when the start of treatment occurs. Bacteria
are actively replicating in acute infection models, when the infec-
tion is performed with a high inoculum, when treatment is started
before the adaptive immunity is activated, or when immunocom-
promised mice are used.174 In a chronicly infected animal, studies
have indicated that bacteria are replicating more slowly.218,219Different research groups have shown that INH has the best
activity in the acute infection models,174 whereas PZA and meﬂo-
quine (MFQ) (unpublished results from CSU as well as NITD) have
better activity in chronic infection models. Overall compounds
showed far greater activity in an acute mouse model [such as the
GKO mouse model] when compared to a chronic mouse model
[using immunocompetent mice], such as described in Hoff et al.174
Another study evaluated the acute (3 day incubation period) and
chronic (28 day incubation period) mouse models after 4 weeks of
treatment and showed that drug activity of the single drugs tested
ranked differently in both models.220 The largest discrepancy was
observed with PZA, which showed it to be highly bactericidal in the
chronic model but permitted bacterial multiplication in the acute
model. Differences with RIF were similar, though not as dramatic.
On the other hand, INH and MXF ranked at the top in the acute
model but near bottom in the chronic model. AstraZeneca showed
very similar data on a poster at ICAAC 2010 on this topic, and
conﬁrmed the effect of PZA. It is our recommendation to use acute
mousemodels for early drug discovery projects because themodels
show a greater sensitivity in identifying active compounds. In a lead
identiﬁcation program, a chronic infection model is more appro-
priate in order to select a lead compound with activity against
slower replicating bacteria.
One needs to recognize that most mouse models are evaluating
activity of single compounds or drug regimens against intracellular
bacteria, as standard laboratory mice primarily develop inﬂam-
matory lesion types. It is important for TB drug development to
realize that the majority of the bacilli in an advanced disease state
are in fact extracellular organisms located in necrotic lesions,174 as
is seen in human cavitary disease.221 On the premise that bacterial
persistence is determined, at least in part, by microenvironmental
conditions (e.g. hypoxia, nutrient depletion, low pH) found in
caseating and necrotic lung lesions, it has been suggested that the
mouse model may not faithfully represent sterilizing activity of
new tuberculosis drugs. Up to date, however, there is no data
available yet that supports this hypothesis. Therefore, the evalua-
tion of the predictive value of mouse and other animals models for
clinical trials deﬁnitely warrants further investigationwhich will be
possible in future with more new drugs being currently evaluated
in clinical trials.
In conclusion, the differences in host immune response among
the different animal models infected with M. tuberculosis result in
a wide variety of granulomatous lesion types which will inﬂuence
the location, metabolism and state of the bacilli and which even-
tually will determine the drug responsiveness. Increasing our
understanding of lesion morphologies as well as the location of
bacilli among the different animal models is vital in designing
different levels of stringency for testing new drugs.
3.6.3. Choice of the M. tuberculosis strain
M. tuberculosis H37Rv was the TB strain most commonly refer-
enced in our survey for both in vitro and in vivomodels for TB drug
testing. The notion of H37Rv as a ‘standard reference’ strain should
be used with some caution though. After our conversations with
investigators, it was often not entirely clear what the exact origin
and background was of the H37Rv strain used (usually it was re-
ported to us as being ‘received from a colleague’), and at times no
special precautions were taken into account for strain culturing and
propagation to retain virulence or to limit the passage number.
Although a recent publication showed that animal passaging of
M. tuberculosis strains prior to quantitative virulence testing in
mouse or guinea pig models does not enhance or restore potency to
strains [that may have lost virulence due to in vitro passaging], the
authors urge investigators to verify virulence of parental strains
before genetic manipulations are undertaken or other comparisons
Table 10
Characterized M. tuberculosis clinical isolates available to researchers worldwide
(strains kindly provided by Drs. M. Kato-Maeda and P. Small, Francis J Curry National
Tuberculosis Center, University of California, San Francisco, CA).
Resources for researchers
Identiﬁer Lineage Available
through
ATCC/BEI
Publications
X001354 East African
Indian
Yes Gagneux et al. PNAS 2006,
Hershberg et al. PLoS Biology 2008,
Comas et al. PLoS ONE 2009,
Comas et al. Nature Genetics 2010
X004439 East Asian Yes Gagneux et al. PNAS 2006,
Hershberg et al. PLoS Biology 2008,
Comas et al. PLoS ONE 2009,
Comas et al. Nature Genetics 2010
X003899 IndoOceanic Yes Gagneux et al. PNAS 2006,
Hershberg et al. PLoS Biology 2008,
Comas et al. PLoS ONE 2009
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a group of investigators which assessed the divergence of the
genome sequences among H37Rv strains in use by six different
laboratories.165 The idea of having well-established reference
M. tuberculosis strains with a full chain of custody, good growth
characteristics and low passage number is deﬁnitely a necessity.
This leads, however, to the more important question of how
conﬁdent arewe that the newer drug combinationswill be effective
against current clinical strains. M. tuberculosis is a member of the
M. tuberculosis complex, and genetic diversity has recently been
linked to clinical, pathogenic, and immunologic heterogeneity in
disease progression and outcomes.223e229 Strains are currently
being classiﬁed into six major phylogenic clades: East African, East
Asian, Euro-American, Indo-Oceanic, and two West African
(Mycobacterium africanum) types.230,231 Several studies have re-
ported different biological, clinical, or epidemiological behaviors of
the various strains, deﬁned by their geographical location or strain
type.165,225,232,233 In addition, strains have also been shown to vary
signiﬁcantly in virulence in animal infection models as measured
by survival, bacterial loads in target organs, histopathology,234,235
and the severity of pulmonary and extrapulmonary lesions, as
well as the immune response engendered after infection. All these
recent reports show that M. tuberculosis strains are more geneti-
cally diverse than was previously recognized.223,226,233,236 Results
from this project thus far, strongly urge investigators to repeat and
conﬁrm ﬁndings against another M. tuberculosis laboratory or
current clinical isolate. For this purpose, the M. tuberculosis clinicalTable 11
NIH/NIAID Services and contracts available to researchers.
Services for researchers available research programs at the NIH/NIAID
Activity NIH Servi
Investigator-initiated grant applications in all areas of TB NIAID’s M
Biological
initiatives
HIV/TB research. Response to currently active initiatives
for fundamental and translational science in MDR/XDR TB
Screening
and precli
chemothe
pretheraa
Pages/inv
Evaluate the pharmacology of existing and new drug
candidates in animal models of TB disease.
In vitro an
drugs and
Characterize the genome and drug resistance markers of
drug resistant Mtb strains
Sequencin
gov/LabsA
brc/ niaidisolates do not necessarily have to be drug resistant in order to rank
order drug regimens for bactericidal activity or relapse of infection,
as there is no evidence of a correlation between virulence and drug
resistance in present clinical isolates.234 For relapse studies, the
presence of regulatory T-cells which suppress T-cell
activation237e239 might be of importance and this immune cell
population is not expressed after infection by all TB strains.237,240 In
Table 10, we list a few resources that can provide characterized
M. tuberculosis strains (clinical strains) to be used by investigators
worldwide. Table 11 lists websites and resources available to
researchers and drug developers available from the NIH. More
studies using various clinical strains are required to increase our
basic knowledge on disease pathogenesis in relation to drug
treatment.
3.6.4. Enumeration methods of bacteria
The activity of an investigational drug or regimen has been in
recent years mostly determined by the reduction of colony forming
units (CFU) of M. tuberculosis by dilution of organ homogenates on
solid agar 7H11 plates. Plating of the organ homogenates has
always been the gold standard for quantifying drug efﬁcacy in vivo.
However, drug discovery efforts are often times held up by this time
consuming step requiring an incubation period of the bacterial
plates of 3e4 weeks. For early drug discovery efforts, more efforts
are being investigated lately for indirect, but more rapid, methods
to ‘measure’ the bacterial load: such as the luciferase readout241,242
or ﬂuorescence.243 These novel detection methods will undoubt-
edly accelerate the TB drug discovery process by delivering an
immediate readout on the efﬁcacy of an experimental compound at
either time of sacriﬁce (for luciferase readout) and even in live
animals in real time (ﬂuorescence). Thorough validation, however,
is not available as of yet andwould be required before these indirect
methods can replace the enumeration by CFU for all drug classes.
Another discussion took place at several occasions during this
project, pointing out that perhaps not all bacteria can be identiﬁed,
cultured or visualized by current methods. The discussion started
with the recent introduction of liquid culture media for the diag-
nostic evaluation of clinical specimens for suspected tubercu-
losis.244 The question then became whether drugs or regimens
which preferentially kill certain bacillary populations would give
rise to a ‘ﬂawed’ readout by only culturing certain subsets of
bacteria on solid agar. If liquid cultures of organ homogenates allow
the growth of TB subpopulations that will not grow on solid media,
the parallel evaluation in liquid and in solid cultures might offer an
opportunity to study drug effects on subpopulations in different
metabolic states. This idea was proposed for EBA clinical trials,244ces Resource/URL NIH Contact
icrobiology and Infectious Diseases
Resources Repository; Partnership
for the development of product candidates
T. Pickett
, microbiological activity, animal testing
nical development of new TB
rapeutics: /LabsAndResources/ resources/dmid/
gents/, and/Labsandresources/resources/dmid/invitro/
itro.aspx, and http://nihroadmap.nih.gov/raid/
T. Parker
B. Spinelli
M. Kurilla
M. Ussery
M. Nasr
J. Boyce
d in vivo PK/PD models, testing of individual
drug regimens
T. Parker
g, molecular genetics, bioinformatics: niaid.nih.
ndResources/resources/
.nih.gov/LabsAndResources/resources/gsc/
M. Giovanni
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and therefore should be tested.
This question might even be more relevant in animal models
with a greater variety in granulomatous lesion types where bacilli
are located in different environments (such as in necrotic, closed or
cavitary lesions) and hence might have different metabolic stages.
Classical studies have reported on those non-culturable bacilli from
closed lesions.245 In those times it was difﬁcult to grow bacteria
from such lung lesions, often as not the calciﬁed lesions from both
lungs and lymph nodes were found not to be infectious, but certain
long term culturing exercises could regrow bacteria in closed
lesions. In a way this is returning to the “viable but non-culturable”
debate of old, but in a new light of current drug development.
3.6.5. PK/PD issues
As we mentioned before, this document mainly focuses on the
in vitro and in vivo methodologies required for activity testing
against M. tuberculosis and less on methodologies that are utilized
in drug development in general such as compound preparation and
storage, ADME, pharmacokinetics and pharmacodynamics and
impact of drug formulation on in vivo efﬁcacy. However, there are
just a few points of discussion relating to TB speciﬁcally that are
addressed here.
Generally, initial in vivo efﬁcacy experiments will use mono-
therapy with high drug doses in order to give the new chemical
entity the best chance of success and provide in vivo proof of
concept. For combination therapy trials, the drug dose is estab-
lished after pharmacokinetic analysis based on a dose with equiv-
alent AUC in humans if available. Dose fractionation studies are also
feasible in mice and can determine the PK features that drive
bacterial killing (pharmacokinetic effect, PD). Recent such studies
have improved our understanding of the PK-PD of INH, RIF and the
ﬂuoroquinolones.246,247 These experiments may inform clinical
development with regard to optimal dosing strategies or might be
required to understand clinical data. In the case of PA-824 where in
a clinical EBA trial no dose response was observed,248 dose-
fractionation studies in mice by E. Nuermberger et al. at JHU have
shown that the major PK parameter driving bactericidal activity is
time above MIC,249 which explains the clinical EBA data entirely.
The same was the case for TMC-207 which did poorly in the initial
days of the EBA clinical trial,250 which was repeated and showed
the same results in a mouse model.250 These experiments are very
labor-intensive however, and not very amenable to long-term
models including relapse. TB drugs will always be used in combi-
nation, and therefore PK analysis should also address drugedrug
interaction and evaluating PK parameters driving bactericidal
killing when drugs are administered in combination. Of signiﬁ-
cance, these PK parameters might be very well different for the
various stages during TB treatment, either in the earlier bactericidal
stage or later when killing the last 1% persisting bacilli. The ques-
tion is how far to take these PK/PD studies in animalmodels prior to
going to clinical trials, or do we only utilize these labor-intensive
studies when certain questions arise? The CPTR (Critical Path for
a New TB Regimen) effort will release shortly a white paper
focusing on gaps and issues in advancing drug regimens to the
clinic and will also address speciﬁcs on the dose selection of TB
drugs in regimens in mice and man.
3.6.6. Relapse studies
During our visits with laboratories involved in TB Drug devel-
opment, a recurring point of discussion was whether relapse
studies in mice are required for the preclinical testing of a new lead
compound in a drug regimen. Relapse studies entail labor-intensive
mouse studies of up to 9 months with large mouse numbers per
group to have sufﬁcient statistical power. They usually also requiretreatment regimens of various lengths, making this a time-
consuming and expensive phase of preclinical testing of a new
drug entity in a regimen. Until more recently it was mostly
perceived that the initial bactericidal activity of a TB drug regimen
was generally speaking correlated with relapse of infection after
cessation of treatment. No convincing published data was available
that showed relapse studies are indeed adding information to the
bactericidal activity of a new regimen. Recently, an important
publication by Andries et al showed that relapse studies give
additional information regarding the sterilizing properties of
a regimen.166 In the described study, a rank order was determined
of the bactericidal and sterilizing potencies of several combination
regimens, and results showed that certain drug regimens with very
good bactericidal properties did not necessarily have good steril-
izing properties (Table 8). Another example from Johns Hopkins
University using drug combinations of standard drugs and PA-824
demonstrated that bactericidal activity and sterilizing activity,
while being close, did not exactly correlate.251 Our head-to-head
experiments (described in Section 2.6) also showed that bacteri-
cidal activity and sterilizing activity for the drug combinations
tested did not always correlate.164 We observed similar efﬁcacy of
MRZ and HRZ over the initial months of treatment, whereas the
relapse rates for the MXF-containing regimen were signiﬁcantly
lower than these for the standard drug regimen for IV infected
mice. Clinical trials to evaluate the superiority of the MXF-
containing regimens to the standard regimens will provide the
deﬁnite answer to the question on the predictive value of the
mouse model and are currently underway.
Of signiﬁcance, the lack of correlation between bactericidal and
sterilizing potencies seen in the mouse model also questions the
usefulness of the current biomarkers in clinical trials for relapse-
free cure (sterilization). Current biomarkers are based on bacteri-
cidal potency measures such as 2-month sputum conversion of
serial sputum colony counts in TB patients.252 A discrepancy
between bactericidal and sterilizing potencies of regimens has
previously been observed in clinical trials, in which the relative
proportions of culture conversion after 8 weeks of treatment were
not predictive of relapse rates.253 It was suggested that there is
a link between the 2-month sputum culture conversion and
relapse, but for various reasons that correlation is not
straightforward.254
A recent initiative by the Gates Foundation (Critical Path to New
TB Regimens, or CPTR) will stimulate development of new combi-
nation regimens (of new investigational drugs along with existing
TB drugs) to avoid developing each drug sequentially over decades
to come.255 Although there is no doubt that the CPTR approach will
lead to more effective drug regimens, it will become crucially
important to select the most promising combinations from
preclinical studies for both bactericidal and sterilizing activity to
advance and be tested clinically. Since the regimens will mainly
consist of new drug entities, relapse studies in different mouse
models will be required to conﬁrm the improved efﬁcacy over the
standard regimen. Different drugs have varying activities against
the various metabolic states of TB subpopulations observed in the
lung (in sputum, necrotic or cavitary lesions, closed lesions), and
therefore a careful dissection of the bactericidal and sterilizing
contributions of a single drug of the novel regimen during the
length of treatment would be preferred to be able to rationally
design the most potent regimen.
Our head-to-head experiments focused primarily on the
comparison of three mouse infection models using Balb/c mice.164
In most of the early studies though, investigators were primarily
using the outbred Swiss mice which were inoculated generally via
the IV route.147,166,210 From our studies and by others, it is clear that
it takes longer treatment times to achieve cure in the IV infected
Text box 7.
Remaining issues and questions on in vivo efficacy models
 Standardization is required within every laboratory; but
the variety of different mouse models across laborato-
ries is recognized to be valuable
 The origin of M. tuberculosis strains with limited
passage number and the propagation conditions to
retain virulence are critical parameters. More studies
are required to study the relationship of clinical strains
and drug treatment
 Bactericidal efficacy is not always predictive for steril-
izing activity of a drug regimen in mice; therefore
relapse studies are required
 Further studies are required to see whether ranking of
newer drug regimens for sterilizing activity are similar
regardless of IV and aerosol infection
 Are other animal models more predictive of clinical
outcome compared to the mouse model?
 Further studies are required to re-evaluate the CFU
readout as a determinant of drug efficacy; liquid media
may be a more sensitive growth indicator
 Should there be a standard way of reporting animal
model data, and collection all in vivo data in a central
database?
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mouse model infected by aerosol.164,209,211 For instance, the drug
regimen [RPT, MXF and PZA] required only 10 weeks of treatment
to obtain a relapse-free cure in the aerosol mouse model,211
versus > 4 months in the IV mouse model.166 It is also apparent
in the IV mouse models that the relapse rates change less
dramatically compared to the Balb/c mice when increasing the
treatment times, which might limit the ability to document
statistically signiﬁcant differences depending on the time and
number of relapse time points taken. A typical result with RHZ for
instance in reported studies with Swiss micemay show 80% relapse
at 4 months, 50% at 5 months, and 25% at 6 months of treatment.
These results are barely showing sufﬁcient differences in activity
over the timepoints used to produce statistically signiﬁcant differ-
ences in relapse rates. With Balb/c mice after a high dose aerosol
infection, typical relapse rates are 75% after 4 months of HRZ, 17% at
5 months, and 0% after 6 months. These data illustrate that esti-
mates of minimal treatment durations are different in the various
mouse models, and therefore should be carefully assessed. The
most important question, however, is to know whether the rank
order of the sterilizing activity of drug regimens would be the same
regardless of themouse infectionmodel used. A head-to-head 2 2
factorial comparison of drug regimens in relapse studies for
instance, using IV infected Swiss mice (outbred) versus aerosol
infected Balb/c mice (inbred) has not been done and would be of
great interest. In the meantime, we recommend the evaluation of
the rank order of sterilizing efﬁcacies of new treatment regimens
preferably in two different mouse models which might give the
ultimate conﬁrmation prior to going to clinical trials.
3.6.7. Reporting of animal model data
Investigators will often not publish negative results and opti-
mism bias permeates the ﬁeld. A recommendation for publication
of negative results and adoption of uniform reporting requirements
should be put forth. There should be a rigorous systematic review
or meta-analysis before embarking on human trials as has been
recommended in the past. Hackam et al. in a recent editorial about
the issues in translating animal research into clinical beneﬁt,256
points out the presence of methodological biases in animal exper-
imentation as well as inadequacy of animal models resembling
human pathophysiology as the major culprits. The suggestions that
are put forward can be applied to TB research. A better uniform
reporting system is needed where all animal data is collected,
positive and negative, and available for investigators, regulators
and funding agencies. If multiple data sets are available this would
allow for more systemic reviews of a drug regimen in order to do
meta-analysis studies as are performed in clinical trials. Another
suggestion from Hackam et al. is to register animal experiments
which would reduce publication bias and therefore provide a more
comprehensive, informed view before proceeding to clinical trials.
In themeantime, it is prudent to be skeptical about the applicability
of animal model data to the clinical domain, which is something
investigators in TB drug evaluations are well aware of.
3.7. Summary and ﬁnal recommendations
Since new drugs need to be tested in animals before going to
man it is crucial that the important parameters of animal models
be identiﬁed and variables of experimental methodology be
understood. This is especially important now that more
compounds than ever will advance to clinical trials and in light of
the CPTR program. We have re-evaluated protocols and collected
information that hopefully can assist laboratories, both new and
experienced, to accelerate the process of TB drug discovery and
development. We have identiﬁed historical and contemporarymethodologies and collected protocols and publications from
universities, companies and institutions engaged in this work via
an electronic survey and personal visits. In order to make progress
in a ﬁeld of diverse methodologies, different parameters in assays
and mouse models were identiﬁed and tested in head-to-head
experiments in the laboratory. To that effect, we compared three
of the most widely used mouse infection models, which are the
low dose aerosol infection model, a high dose aerosol infection
model and the intravenous infection model for tuberculosis.
Results of in vivo efﬁcacy testing of the standard drug combination
were shown to be similar regardless the strain of mice used. The
results of both the bactericidal and sterilizing activity for the drug
combinations tested were found to be independent of the route of
infection, inoculum size, the formulation of RIF, or the timing of
administration for RIF in combination (either 1 h prior or after) for
the drug regimens tested. The results showed that the most
important variable in our experiments was the M. tuberculosis
strain used for infection. Whether this variability is related to the
origin of the strain, the method of propagation, the passage
number of the strain still needs to be investigated further. The
following suggestions and recommendations resulted from this
work:
B According to most of those who participated in this effort, the
mouse model is still the main animal model of choice for TB
drug development as it represents the only animal model that
has been validated to date by reproducing regimens and
treatment durations known to work in patients.
B Different laboratories should embrace the variety in mouse
models used for TB drug development. The consensus on the
topic of assay standardization throughout this effort was that
therewas farmore to be learned frommultiplemouse infection
models used across different laboratories instead of relying on
one single infection model used by every laboratory.
B Standardization of the protocols and methods used within
a laboratory is deﬁnitely recommended. Standardization in
terms of using a certain inoculum of bacteria, start of infection,
S.G. Franzblau et al. / Tuberculosis 92 (2012) 453e488 483start of treatment, appropriate qualitative controls to track the
infectivity and growth characteristics of the M. tuberculosis
strain in every experiment and inclusion of appropriate drug
controls.
B In the in vivo head-to-head experiments described here, the
M. tuberculosis strain was found as one of the most important
variables that can change the outcome of the in vivo efﬁcacy
trial in mice. Therefore, we highly recommend the conﬁrma-
tion of in vivo efﬁcacy results against a differentM. tuberculosis
strain than the one used in an initial experiment. If possible,
the animal study should be repeated with a current clinical
M. tuberculosis strain [belonging to one or more different
clades230]. Of importance, it is recommended to only use
M. tuberculosis strains that are fully characterized (genetically),
with good growth characteristics, limited passage number,
propagated appropriately to retain virulence, and which have
a complete chain of custody.
B There is not one single strategic plan or testing sequence that
can be followed for every new TB compound, and this is
especially true for late stage of preclinical testing (some
examples include PA-824, MXF, TMC-207 as mentioned above).
Early in drug discovery, the testing for in vivo activity of a single
compound in mice is straightforward. In the stage of drug
regimen optimization, however, a more tailored approach is
required for every new investigational entity. All features
including PK/PD, protein binding, activity against NRP bacilli,
Minimal Effective Dose, Minimal Bactericidal Dose, in vivo
tolerability, drugedrug interactions, etc. will determine the
strategy for advancing the compound into combination studies
in mice.
B For all drug combination mouse studies, the recommendation
is not to repeat the evaluation of drug regimens in the exact
same mouse infection model, but to perform the conﬁrmatory
studies in a mouse model sufﬁciently different from the initial
one (using a different mouse strain, other route of infection,
other TB strain). This is to increase conﬁdence and ensure the
new drug combination is more potent compared to the stan-
dard drug combination prior to advancing to clinical trials.
Final conﬁrmation of results in a second laboratory would
therefore be highly encouraged.
B Of utmost importance, any unexpected antagonism between
new lead entities should be repeated before removal of
a potentially potent combination (e.g. antagonism in the
standard regimen, and between TMC-207 and PA-824 (PA). The
same applies for any unexplained synergistic activities
between drugs in the mouse model.
B The conﬁrmation of results in a second animal model [such as
the guinea pig, the rabbit, non-human primates, the Kramnik
mouse model, etc.] to address evaluation of efﬁcacy against
persisting bacilli in advanced lesions is currently of theoretical
concern only, as comparative studies between the mouse and
other animal models are largely missing and their predictive
value to clinical data has not been shown yet.
B Relapse studies are an essential part of evaluating the potency
of a drug regimen given that the ranking of the bactericidal and
sterilizing potencies of the regimens can be different.
B In any combination treatment study where a substitution is
madewith a new drug in a regimen (e.g. removal or an addition
of another agent), it is important to include all appropriate
control arms.
B It is critically important to continue to repeat and conﬁrm
results by others by duplicating every detail of the original
work.
B Early discussions and interactions with representatives of
regulatory agencies are encouraged and can provide criticalguidance on the types and design of studies (both preclinical
and clinical) likely to facilitate TB drug development.
In summary, given the wide heterogeneity of human clinical TB
it may not necessarily be a good practice to rely on a uniform set of
harmonized experimental methods. Protocols used by each labo-
ratory that have developed and standardized their methods, typi-
cally generate reproducible results in that laboratory. We therefore
recommend preclinical animal studies for TB drug development not
be standardized as such but that critical studies are conﬁrmed in
a second laboratory using a different mouse, different strain(s) of
TB, with or without infecting via another route and include the
appropriate treatment control groups, prior tomoving to expensive
human trials.
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